Eagle Pharmaceuticals (EGRX) 10-K 15 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information Document - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 03, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Eagle Pharmaceuticals, Inc.
Entity Central Index Key	827,871
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		15,227,165
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 364,085,254

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 52,820	$ 79,083
Accounts receivable	42,194	26,267
Inventory	2,739	15,042
Prepaid expenses and other current assets	11,357	1,865
Total current assets	109,110	122,257
Property and equipment, net	3,316	2,205
Intangible assets, net	33,372	0
Goodwill	39,743	0
Deferred tax asset, net	28,643	0
Other assets	136	143
Total assets	214,320	124,605
Current liabilities:
Accounts payable	14,716	3,857
Accrued expenses	25,237	24,405
Current portion of contingent consideration	1,012	0
Deferred revenue	0	6,000
Total current liabilities	40,965	34,262
Contingent consideration, less current portion	22,129	0
Commitments and contingencies
Stockholders' equity:
Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding	0	0
Common stock, $0.001 par value; 50,000,000 shares authorized; 15,890,862 and 15,636,387 issued as of December 31, 2016 and 2015, respectively	16	15
Additional paid in capital	213,872	197,440
Accumulated deficit	(25,659)	(107,112)
Treasury stock, at cost, 566,838 shares as of December 31, 2016	(37,003)	0
Total stockholders' equity	151,226	90,343
Total liabilities and stockholders' equity	$ 214,320	$ 124,605

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	1,500,000	1,500,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value per share (dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares, issued (in shares)	15,890,862	15,636,387
Treasury stock, shares (in shares)	566,838

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Revenue:
Product sales	$ 1,506	$ 40,646	$ 12,968	$ 4,626
Royalty revenue	4,094	99,040	8,259	10,708
License and other revenue	0	49,796	45,000	3,765
Total revenue	5,600	189,482	66,227	19,099
Operating expenses:
Cost of product sales	1,782	34,320	7,762	5,042
Cost of royalty revenue	2,707	20,986	7,885	6,672
Research and development	3,986	30,262	27,855	16,816
Selling, general and administrative	3,690	52,313	20,165	9,326
Gain on sale of asset	0	(1,750)	0	0
Total operating expenses	12,165	136,131	63,667	37,856
Income (Loss) from operations	(6,565)	53,351	2,560	(18,757)
Interest income	1	84	25	31
Interest expense	(1)	(8)	(11)	(8)
Change in value of warrant liability	0	0	0	(573)
Other income	0	0	0	35
Total other income/(expense)	0	76	14	(515)
Income (Loss) before income tax benefit	(6,565)	53,427	2,574	(19,272)
Benefit from (provision for) income taxes	1,059	28,026	(3)	1,295
Net Income (Loss)	(5,506)	81,453	2,571	(17,977)
Less dividends on Series A, B, B-1 and C Convertible Preferred Stock	0	0	0	(1,666)
Net income (loss) attributable to common stockholders	$ (5,506)	$ 81,453	$ 2,571	$ (19,643)
Earnings per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.39)	$ 5.24	$ 0.17	$ (1.97)
Diluted (in dollars per share)	$ (0.39)	$ 4.96	$ 0.16	$ (1.97)
Weighted average number of common shares outstanding:
Basic (in shares)	14,032,828	15,533,681	15,250,154	9,955,937
Diluted (in shares)	14,032,828	16,434,104	16,253,781	9,955,937

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B-1 Convertible Preferred Stock	Series C Convertible Preferred Stock	Series C Preferred Stock Warrants	Common Stock	Common StockSeries A Convertible Preferred Stock	Common StockSeries B Convertible Preferred Stock	Common StockSeries B-1 Convertible Preferred Stock	Common StockSeries C Convertible Preferred Stock	Common StockSeries C Preferred Stock Warrants	Additional Paid-In Capital	Additional Paid-In CapitalSeries A Convertible Preferred Stock	Additional Paid-In CapitalSeries B Convertible Preferred Stock	Additional Paid-In CapitalSeries B-1 Convertible Preferred Stock	Additional Paid-In CapitalSeries C Convertible Preferred Stock	Additional Paid-In CapitalSeries C Preferred Stock Warrants	Treasury Stock	Accumulated Deficit
Number of shares outstanding, beginning balance (in shares) at Sep. 30, 2013							3,048,000
Stockholders' equity attributable to parent, beginning balance at Sep. 30, 2013	$ (87,929)						$ 3						$ 14,204							$ (102,136)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	606												606
Issuance of common stock in connection with initial public offering, including underwriter's over-allotment, net of offering costs and underwriter's discount (in shares)							3,450,000
Issuance of common stock in connection with initial public offering, including underwriter's over-allotment, net of offering costs and underwriter's discount	46,048						$ 3						46,045
Conversion of preferred shares to common stock, (in shares)								2,332,000	1,980,000	1,456,000	1,720,000	32,000
Conversion of preferred shares to common stock, value		$ 20,377	$ 30,612	$ 19,756	$ 20,903	$ 2,280		$ 3	$ 2	$ 1	$ 2			$ 20,374	$ 30,610	$ 19,755	$ 20,901	$ 2,280
Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants (in shares)							2,000
Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants	21												21
Issuance of common stock upon exercise of stock option grants (in shares)							12,000
Issuance of common stock upon exercise of stock option grants	65												65
Dividends on Convertible Preferred Stock and forfeitures of dividends on conversion to common													(17,602)							17,602
Net income (loss)	(17,977)																			(17,977)
Dividends on Convertible Preferred Stock	(1,666)																			(1,666)
Number of shares outstanding, ending balance (in shares) at Sep. 30, 2014							14,032,000
Stockholders' equity attributable to parent, ending balance at Sep. 30, 2014	33,096						$ 14						137,259							(104,177)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 284												284
Issuance of common stock upon exercise of stock option grants (in shares)	4,513						5,000
Issuance of common stock upon exercise of stock option grants	$ 34												34
Net income (loss)	(5,506)																			(5,506)
Number of shares outstanding, ending balance (in shares) at Dec. 31, 2014							14,037,000
Stockholders' equity attributable to parent, ending balance at Dec. 31, 2014	27,908						$ 14						137,577							(109,683)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	4,051												4,051
Issuance of common stock in connection with initial public offering, including underwriter's over-allotment, net of offering costs and underwriter's discount (in shares)							1,389,000
Issuance of common stock in connection with initial public offering, including underwriter's over-allotment, net of offering costs and underwriter's discount	$ 54,331						$ 1						54,330
Issuance of common stock upon exercise of stock option grants (in shares)	211,190						211,000
Issuance of common stock upon exercise of stock option grants	$ 1,482												1,482
Net income (loss)	2,571																			2,571
Number of shares outstanding, ending balance (in shares) at Dec. 31, 2015							15,637,000
Stockholders' equity attributable to parent, ending balance at Dec. 31, 2015	90,343						$ 15						197,440						$ 0	(107,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 9,768												9,768
Issuance of common stock upon exercise of stock option grants (in shares)	214,194						214,000
Issuance of common stock upon exercise of stock option grants	$ 3,619						$ 1						3,618
Common stock repurchases	(37,003)																		(37,003)
Net income (loss)	81,453																			81,453
Common stock issued for the Eagle Biologics acquisition (in shares)							40,000
Common stock issued for the Eagle Biologics acquisition	3,046												3,046
Number of shares outstanding, ending balance (in shares) at Dec. 31, 2016							15,891,000
Stockholders' equity attributable to parent, ending balance at Dec. 31, 2016	$ 151,226						$ 16						$ 213,872						$ (37,003)	$ (25,659)

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income (loss)	$ (5,506)	$ 81,453	$ 2,571	$ (17,977)
Deferred income taxes	0	(30,116)	0	0
Depreciation expense	13	641	112	104
Amortization expense	0	948	0	0
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation	284	9,768	4,051	606
Change in fair value of contingent consideration	0	957	0	0
Gain on sale of asset	0	(1,750)	0	0
Change in fair value of warrant liability	0	0	0	573
Loss on disposal of fixed assets	0	0	273	0
Changes in operating assets and liabilities:
(Increase) in accounts receivable	(4,660)	(15,919)	(14,311)	(2,172)
Decrease (increase) in inventory	52	12,303	(13,800)	(1,294)
(Increase) decrease in prepaid expenses and other current assets	71	(9,423)	(225)	192
(Increase) decrease in other assets	0	(7)	(98)	1
Increase (decrease) in accounts payable	(558)	10,668	356	2,867
Decrease in deferred revenue	(65)	(6,000)	(520)	(3,435)
(Decrease) increase in accrued expenses and other liabilities	2,494	(316)	11,873	6,692
Net cash provided by (used in) operating activities	(7,875)	53,207	(9,718)	(13,843)
Cash flows from investing activities:
Purchase of property and equipment	(11)	(1,590)	(1,881)	(46)
Purchase of short term investments	0	(62,000)	(105,999)	(19,999)
Maturities of short term investments	19,999	62,000	105,999	0
Payment for Docetaxel acquisition	0	(4,850)	0	0
Payment for Ryanodex intangible asset	0	(14,250)	0	0
Purchase of Eagle Biologics, net of cash acquired	0	(26,860)	0	0
Proceeds from sale of diclofenac-misoprostol	0	1,750	0	0
Net cash (used in) provided by investing activities	19,988	(45,800)	(1,881)	(20,045)
Cash flows from financing activities:
Repurchases of common stock	0	(37,003)	0	0
Payment of contingent consideration	0	(286)	0	0
Series C preferred stock offering costs	0	0	0	(1)
Proceeds from exercise of preferred stock warrants	0	0	0	21
Proceeds from issuance of common stock from initial public offering, net of issuance costs	0	0	0	46,069
Proceeds from issuance of common stock from follow-on public offering, net of issuance costs	0	0	54,331	0
Proceeds from common stock option exercise	34	3,619	1,482	65
Net cash (used in) provided by financing activities	34	(33,670)	55,813	46,154
Net increase in cash	12,147	(26,263)	44,214	12,266
Cash and cash equivalents at beginning of period	22,722	79,083	34,869	10,456
Cash and cash equivalents at end of period	34,869	52,820	79,083	22,722
Cash paid during the period for:
Interest	1	8	11	8
Income taxes	0	2,800	482	0
Non-cash operating activities
Landlord contribution to leasehold improvements recorded as deferred rent	0	0	367	0
Non-cash investing activities
Value of common stock issued for the Eagle Biologics acquisition		3,046
Non-cash financing activities
Contingent consideration - business acquisitions	0	22,470	0	0
Conversion of Preferred Stock and Accrued Dividends to Common Stock
Non-cash financing activities
Conversion to Common Stock	0	0	0	91,648
Conversion of Redeemable Warrant Liability to Common Stock
Non-cash financing activities
Conversion to Common Stock	$ 0	$ 0	$ 0	$ 2,280

Organization and Business Activ

Organization and Business Activities	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Activities	Organization and Business Activities Eagle Pharmaceuticals, Inc. (the Company, or Eagle, or we) is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the Food and Drug Administration's ("FDA's") 505(b)(2) NDA regulatory pathway. The Company's business model is to develop proprietary innovations to FDA-approved, injectable drugs, referred to as branded reference drugs, that offer favorable attributes to patients and healthcare providers. The Company has five products currently being sold in the United States under various license agreements in place with commercial partners, including a ready-to-use formulation of Argatroban, Ryanodex ® ,(dantrolene sodium) ("Ryanodex), diclofenac-misoprostol and docetaxel injection, non-alcohol formulation ("Non-Alcohol Docetaxel Injection") and rapidly infused bendamustine RTD ("Bendeka"). The Company has a number of products currently under development and certain products may be subject to license agreements. On February 18, 2014 , the Company closed its initial public offering (the "IPO") whereby the Company sold 3,350,000 shares of common stock, at a public offering price of $15.00 per share, before underwriting discounts and expenses. On March 18, 2014 , the underwriters exercised an over-allotment option granted in connection with the offering of 100,000 shares of common stock at the initial public offering price, less the underwriter discount. The aggregate net proceeds received by the Company from the offering were $46,069 . Included in this amount is $21 received from the exercise of Series C preferred stock warrants for 1,788 shares of common stock. In connection with the IPO, the Company's board of directors approved a one-for-6.41 reverse stock split of the Company's common stock (that resulted in a proportional adjustment to the conversion ratio of the preferred stock warrants). All references to common stock, common stock equivalents and per share amounts have been changed retroactively in these condensed financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an equal amount to the reduction in par value of common stock to additional paid-in capital. On the IPO closing date, all outstanding shares of preferred stock converted into 7,487,928 shares of common stock and the outstanding warrants were net exercised for 32,286 shares common stock at the initial public offering price. These transactions produced a significant increase in the number of shares outstanding which will impact the year-over-year comparability of the Company’s (loss) earnings per share calculations. Additionally, in connection with the closing of the IPO, the Company amended and restated its articles of incorporation to decrease the number of authorized shares of common and undesignated preferred stock to 50,000,000 and 1,500,000 , respectively. On January 20, 2015, the board of directors of the Company authorized a change in the Company’s fiscal year end from September 30 th to December 31 st . The change was intended to better align the Company’s fiscal year with the business cycles of other specialty pharmaceutical companies. As a result of the change in fiscal year, the Company’s 2015 fiscal year began on January 1, 2015 and ended on December 31, 2015. On February 13, 2015, the Company submitted a New Drug Application or NDA to the FDA for Bendeka, which was approved by the FDA on December 7, 2015. Also, on February 13, 2015, the Company entered into an Exclusive License Agreement (the “Cephalon License”) with Cephalon, Inc. ("Cephalon"), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. ("Teva"), for U.S. and Canadian rights to Bendeka for treatment of patients with chronic lymphocytic leukemia (“CLL”) and patients with non-Hodgkin’s lymphoma (“NHL”). Pursuant to the terms of the Cephalon License, Cephalon is responsible for all U.S. commercial activities for the product including promotion and distribution, and the Company is responsible for obtaining and maintaining all regulatory approvals and conducting post-approval clinical studies. Additionally, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , in January 2016, received a $15 million milestone payment related to the FDA approval of Bendeka in December 2015, received $40 million in November 2016 related to the receipt of a unique, product-specific billing code, J-code (J9034), for Bendeka and is currently eligible to receive up to $25 million in an additional sales-based milestone payment. In addition, the Company was entitled to receive royalty payments of 20% of net sales of the product, which increased to 25% on receipt of the J-code. In connection with the Cephalon License, the Company has entered into a supply agreement with Cephalon, pursuant to which the Company is responsible for supplying product to Cephalon. On March 20, 2015, the Company completed an underwritten public offering (the "Follow-on Offering") of 1,518,317 shares of common stock, including the exercise by the underwriters of a 30 -day option to purchase an additional 198,041 shares of common stock. Of the shares sold, 1,388,517 shares were issued and offered by the Company and 129,800 shares were offered by certain selling stockholders. All of the shares were offered at a price to the public of $42.00 per share. The net proceeds to Eagle from this offering, after deducting underwriting discounts and commissions and other offering expenses payable by Eagle, were approximately $54,331 . Eagle did not receive any proceeds from the shares sold by the selling stockholders. The securities described above were offered pursuant to a shelf registration statement declared effective by the Securities Exchange Commission on March 13, 2015. On October 13, 2015, the Company entered into an exclusive U.S. licensing agreement (the "Teikoku Agreement") with Teikoku Pharma USA, Inc. ("Teikoku") to market, sell and distribute Non-Alcohol Docetaxel Injection, an investigational product intended for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. The NDA for Non-Alcohol Docetaxel Injection for these indications was approved by the FDA on December 22, 2015. Under the terms of the agreement, the Company paid an upfront cash payment of $250 upon execution of the agreement which was included in Research and development in the Company's statement of operations in the fourth quarter of 2015. In January 2016, the Company made an additional payment of $4,850 to Teikoku upon FDA approval and NDA transfer to Eagle. In addition, the Company is obligated to pay 25% royalties on future gross profits. The Company accounted for the transaction as a business combination in 2016. The results of operations related to Non-Alcohol Docetaxel Injection have been included in the statements of income from the date of acquisition. The Company did not incur any significant acquisition related costs in connection with the Non-Alcohol Docetaxel Injection acquisition. See Note 14. Acquisitions. On November 4, 2015, the Company entered into a Co-Promotion Agreement (the "Spectrum Agreement") with Spectrum Pharmaceuticals, Inc. ("Spectrum"), under which Spectrum agreed to dedicate 80% of its 32 -person Corporate Accounts Sales Team's time to selling and marketing one of our products through June 2017 . We will have paid Spectrum a base fee of $12.8 million through June 2017. We have the right to extend the initial term of this agreement by six months to December 31, 2017 at our sole election. Any extensions after December 31, 2017 require mutual consent and will be for six months per extension. In preparation for near-term product launches, we are building an internal commercial team anticipated to consist of approximately 50 direct sales representatives, support staff and management who will be a part of our independent commercial organization. On January 11, 2016, the Company entered into an agreement with Albany Molecular Research, Inc. ("AMRI") to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialization in the United States. Under the terms of the agreement, AMRI will develop and initially provide cGMP manufacturing and analytical support for the registration of the new product candidates. The Company and AMRI will share the costs of development, with 37.5% paid by the Company and 62.5% paid by AMRI. The Company will be responsible for advancing the product candidates through clinical trials and regulatory submissions. On March 18, 2016, the Company received a Complete Response Letter from the FDA for EP-6101 ready-to-use ("RTU") bivalirudin ("EP-6101") in which the FDA stated it cannot approve the application in its present form and requested additional information from the Company. Discussions with the FDA to identify an appropriate pathway to approval are ongoing and could include a human study. On March 28, 2016 the FDA denied the Company's request for seven years of orphan drug exclusivity in the U.S., for Bendeka. On March 29, 2016, the Company entered into an asset purchase agreement (the "Diclofenac Asset Purchase Agreement") pursuant to which the Company sold certain intellectual property related to diclofenac-misoprostol in the United States. In consideration of the assets and rights sold under the Diclofenac Asset Purchase Agreement, the Company received a one-time payment at closing of $1.75 million which was recognized as a gain in the first quarter of 2016. In consideration of the rights granted under the agreement, the purchaser will pay the Company a 25% royalty on net profits of diclofenac-misoprostol in the territory for five years from the date of sale. The Company may continue to market diclofenac-misoprostol until such time that the purchaser is able to launch the product. In April 2016, we filed a lawsuit against the FDA arguing that Bendeka is entitled to orphan drug exclusivity as a matter of law (see Part II, Item I. Legal Proceedings). On July 2, 2014, the FDA granted us orphan drug designations for Bendeka for the treatment of CLL and indolent B-cell NHL. The designations were based on a plausible hypothesis that Bendeka is “clinically superior” to a drug previously approved for the same indications. Generally, an orphan-designated drug is eligible for seven years of marketing exclusivity for the orphan-designated indications upon approval of the drug for those indications. If granted, orphan drug exclusivity for Bendeka would run for seven years from December 7, 2015, the date Bendeka was approved. However, the FDA issued a letter decision to us on March 24, 2016, taking the position that Bendeka is not currently eligible for orphan drug exclusivity because it has not been demonstrated to be clinically superior to the drug previously approved for the same indications. On July 11, 2016, the FDA determined that no additional human safety and efficacy data is required for the submission of EP-4104 (dantrolene sodium) for exertional heatstroke ("EHS"), further confirming that a hybrid development program comprised of clinical data from EHS patients and positive preclinical data from animal studies constitutes an adequate regulatory pathway for future NDA submission. Following the completion of the additional animal studies, the NDA was submitted on January 20, 2017. On August 3, 2016, the Company amended our agreement with Lyotropic Therapeutics, Inc. to reduce future royalties related to Ryanodex net sales from 15% to 3% (subject to further reduction upon the occurrence of certain triggering events) in exchange for $15 million , which we recorded as an intangible asset (see Note 15 Intangible assets, net). On August 9, 2016, the Company announced a share repurchase program approved by the Company’s board of directors authorizing the repurchase of up to $75.0 million of the Company’s common stock (the “Share Repurchase Program”). Under the Share Repurchase Program, the Company is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The Share Repurchase Program has no time limit and may be suspended or discontinued completely at any time. The specific timing and amount of repurchases will vary based on available capital resources and other financial and operational performance, market conditions, securities law limitations, and other factors. The repurchases will be made using our cash resources. In any period, cash used in financing activities related to shares repurchased may differ from the comparable change in stockholders' equity, reflecting timing differences between the recognition of share repurchase transactions and their settlement for cash. We repurchased 276,244 shares of common stock for $19.0 million during the fourth quarter of 2016, and a total of 566,838 for $37.0 million in the year ended December 31, 2016. During the quarter-ended September 30, 2016, the Company entered into an amendment to the Cephalon license and supply agreements for Bendeka. The amendment expands the geographical scope of the rights granted under the original agreement to include territories outside the US and Canada. In accordance with this agreement, the Company recorded $1.75 million in license and other revenue on the statements of operations for the year ended December 31, 2016. The Company is also eligible to receive up to $750 thousand on each regulatory approval received in certain additional territories, not to exceed $2.25 million , and royalties on future sales. On November 2, 2016, the Company announced that the Centers for Medicare and Medicaid Services (CMS) established a J-code for Bendeka. The J-code became effective on January 1, 2017. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, facilitating access for patients and Medicare, Medicaid and commercial insurance reimbursement. Under the terms of the Cephalon License, the Company received a $40 million milestone payment upon receipt of the J-code in the fourth quarter of 2016, which we recorded in License and other revenue in the statement of operations for the year ended December 31, 2016. Additionally, this event triggered an increase in the royalty rate from 20% to 25% of Bendeka net sales. On November 16, 2016 the Company entered into an agreement to acquire Arsia Therapeutics (“Arsia”), an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how and subsequently renamed the subsidiary Eagle Biologics, Inc. ("Eagle Biologics"). Under the terms of the stock purchase agreement, we paid approximately $27.2 million in cash and 40,200 shares of Eagle common stock worth $3.0 million at closing. We also agreed to pay up to $48 million in additional payments upon the completion of certain milestones, for aggregate potential payments of $78 million . As part of the agreement, Eagle Biologics founders and Massachusetts Institute of Technology professors, Dr. Robert Langer and Dr. Alexander Klibanov, as well as other key members of the Eagle Biologics team, entered into agreements to work with Eagle to develop new formulations and solve delivery challenges in the large molecules space (see Note 14.)

Transition Period

Transition Period	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Transition Period	Transition Period On January 20, 2015, the board of directors of the Company authorized a change in the Company’s fiscal year end from September 30 th to December 31 st . Accordingly, the Company is presenting audited financial statements for the 3 month period ended December 31, 2014. The following table provides certain unaudited comparative financial information for the same period of the prior year. Three Months Ended 2014 2013 (unaudited) Revenue: Product sales $ 1,506 $ 2,224 Royalty revenue 4,094 3,268 Total revenue 5,600 5,492 Operating expenses: Cost of product sales 1,782 2,670 Cost of royalty revenue 2,707 1,954 Research and development 3,986 2,589 Selling, general and administrative 3,690 1,344 Total operating expenses 12,165 8,557 Loss from operations (6,565 ) (3,065 ) Interest income 1 1 Interest expense (1 ) — Change in value of warrant liability — (191 ) Total other (expense) — (190 ) Loss before income tax benefit (6,565 ) (3,255 ) Income tax benefit 1,059 — Net Loss $ (5,506 ) $ (3,255 ) Less dividends on Series A, B, B-1 and C Convertible Preferred Stock — (1,132 ) Net loss attributable to common stockholders $ (5,506 ) $ (4,387 ) Loss per share attributable to common stockholders Basic and diluted $ (0.39 ) $ (1.44 ) Weighted average common shares outstanding Basic and diluted 14,032,828 3,048,131

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Reclassifications Certain reclassifications have been made to prior year amounts to conform with the current year presentation. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature. The Company, at times, maintains balances with financial institutions in excess of the FDIC limit. Fair Value of Financial Instruments The Company's financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and contingent consideration from acquisitions. The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximate their fair values due to their short term maturities. Contingent consideration is recorded at fair value. Short Term Investments Investments consisted of U.S. Treasury securities that have an original maturity of greater than three months and typically less than 180 days. The Company's investments were classified as Level 1 and available-for-sale and are recorded at fair value, based upon quoted market prices. No gains or losses on investments are realized until the sale occurs or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Fair Value Measurements U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of interest-bearing cash and cash equivalents and short term investments are classified as Level 1 for all periods presented. The fair value of contingent consideration is classified as Level 3 for the period presented. The Company is required by U.S. GAAP to record certain assets and liabilities at fair value on a recurring basis. Company marks the value of its warrant liability to market and recognize the change in valuation in its statement of operations each reporting period. Determining the warrant liability to be recorded required the Company to develop estimates to be used in calculating the fair value of the warrant. Since these preferred stock warrants did not trade in an active securities market, the Company recognized a warrant liability and estimated the fair value of these warrants using a Probability-Weighted Expected Returns valuation model. Therefore, the warrant liability was considered a Level 3 measurement. All warrants outstanding immediately prior to the IPO were net exercised in connection with the initial public offering. There were no outstanding warrants as of December 31, 2016 and 2015. Intangible Assets The Company capitalizes and includes in intangible assets the costs of acquired product licenses and developed technology purchased individually or identified in a business combination. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization The Company amortizes its definite-lived intangible assets using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. We will evaluate the potential impairment of other intangible assets if events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Events giving rise to impairment are an inherent risk in our industry and many factors cannot be predicted. Factors that we consider in deciding when to perform an impairment review include significant changes in our forecasted projections for the asset or asset group for reasons including, but not limited to, significant under-performance of a product in relation to expectations, significant changes or planned changes in our use of the assets, significant negative industry or economic trends, and new or competing products that enter the marketplace. The impairment test is based on a comparison of the undiscounted cash flows expected to be generated from the use of the asset group and its eventual disposition to the carrying value of the asset group. If impairment is indicated, the asset is written down by the amount by which the carrying value of the asset exceeds the related fair value of the asset with the related impairment charge recognized within the statements of operations. We did not identify any impairment to our definite-lived intangible assets in the periods presented. With respect to determining an asset’s fair value and useful life, because this process involves management making certain estimates and because these estimates form the basis of the determination of whether or not an impairment charge should be recorded, these estimates are considered to be critical accounting estimates. Such impairment charges may be material to our results. Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment model requires a two-step method for determining goodwill impairment. In the first step, we determine the fair value of our reporting units using an appropriate valuation methodology. If the net book value of a reporting unit exceeds its fair value, we would then perform the second step of the impairment test which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations. Any residual fair value is allocated to goodwill. An impairment charge is recognized only when the implied fair value of our reporting unit’s goodwill is less than its carrying amount. We did not identify any impairment to goodwill during the periods presented. Acquisition-Related Contingent Consideration Contingent consideration related to a business combination is recorded at the acquisition date at the estimated fair value of the contingent payments. The acquisition date fair value is measured based on the consideration expected to be transferred using probability-weighted assumptions and discounted back to present value. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. The fair value of the acquisition-related contingent consideration is re-measured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in the consolidated statements of operations. Concentration of Major Customers and Vendors The Company is dependent on commercial partners to market and sell Argatroban and Bendeka. The Company's customers for Argatroban are its commercial and licensing partners, therefore, the Company's future revenues are highly dependent on these collaboration and distribution arrangements. The Company received a $30 million upfront payment during February 2015 and earned a $15 million milestone payment received in January 2016 upon product approval in December 2015 under the terms of the Cephalon License- See "revenue recognition" below for more detail. The Company received a $40 million milestone payment in December 2016 upon receipt of the J-code. Additionally, this event triggered an increase in the royalty rate from 20% to 25% of Bendeka net sales. The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Net product sales, royalty and license revenues The Medicines Company/Chiesi USA, Inc. 4 % 14 % 36 % 45 % Sandoz, Inc. 5 % 5 % 55 % 53 % Cephalon, Inc. (Teva) 79 % 68 % — % — % Other 12 % 13 % 9 % 2 % 100 % 100 % 100 % 100 % December 31, December 31, 2016 2015 Accounts receivable The Medicines Company/Chiesi USA, Inc. 3 % 35 % Sandoz, Inc. 8 % — % Cephalon, Inc. (Teva) 74 % 57 % Other 15 % 8 % 100 % 100 % Currently, for Argatroban and Bendeka, the Company uses one vendor as its sole source supplier. Because of the unique equipment and process for manufacturing, transferring manufacturing activities to an alternate supplier would be a time consuming and costly endeavor, and there are only a limited number of manufacturers that are capable of performing this function for the Company. Inventory Inventory is recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in value is first recognized. In most instances, inventory is shipped from the Company's vendor directly to the Company's customers. Property and Equipment Property and equipment are stated at cost. Depreciation is computed over the estimated useful lives of the assets utilizing the straight-line method. Leasehold improvements are being amortized over the shorter of their useful lives or the lease term. Redeemable Convertible Preferred Stock The carrying value of redeemable convertible preferred stock was increased by periodic accretions, using the interest method so that the carrying amount would equal the redemption amount at the earliest redemption date. Research and Development Expense Costs incurred for research and product development, including costs incurred for technology in the development stage, are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Advance payments for goods or services that will be used for future research and development activities are capitalized as deferred cost and expensed as the related goods are delivered or services performed. Recoveries of previously recognized R&D expenses from third parties are recorded as a reduction to R&D expense in the period it becomes realizable. Advertising and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs were $14,784 , $4,752 , $1,556 , and $2,506 for fiscal 2016, fiscal 2015, the transition period, and fiscal 2014, respectively. Income Taxes We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. Since our inception, we have incurred substantial cumulative losses and through the third quarter of 2016 we recorded a full valuation allowance against our net deferred tax assets which was largely made up of our net operating loss carryforward. In the fourth quarter of 2016, the Company reversed the reserve on its net deferred tax asset (See Note 10 - Income Taxes). ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Revenue Recognition Product revenue - The Company recognizes net revenue on sales to its commercial partners and to end users. In each instance, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered and collectability is reasonably assured. Revenue on sales to commercial partners relates to Argatroban and Bendeka. The Company’s commercial partners can return product within specified timeframes if the product does not meet certain inspection tests. Sales to our commercial partners are presented gross primarily because the Company is the primary obligor in the arrangement, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue on sales to end users for Non-Alcohol Docetaxel Injection, Ryanodex and diclofenac-misoprostol are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. The Company has a product returns policy on some of its products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. The Company's estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. The Company has terms on sales of Ryanodex by which the Company does not accept returns. The Company believes that the reserves it has established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amount for reserves to vary. Royalty Revenue — The Company recognizes revenue from license arrangements with its commercial partners' net sales of products. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collectability is reasonably assured. The Company's commercial partners are obligated to report their net product sales and the resulting royalty due to the Company within 25 days for Bendeka and 60 days for Argatroban from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial. License and other income — The Company analyzes each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. When a sale combines multiple elements upon performance of multiple services, the Company allocates revenue for transactions that include multiple elements to each unit of accounting which is deliverable or combination of deliverables under the arrangement that has stand-alone value to the counter-party based on its relative selling price, and recognizes revenue for each unit of accounting when the revenue recognition criteria have been met. The Company follows the selling price hierarchy as outlined in the guidance Revenue Recognition (ASC Topic 605) - Multiple-Deliverable Revenue Arrangements . The guidance provides a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence (“VSOE”), (ii) third-party evidence (“TPE”) if available and when VSOE is not available, and (iii) best estimate of the selling price (“BESP”) if neither VSOE nor TPE is available. The Company uses BESP to determine the stand-alone selling price for such deliverables. The Company has an established process for developing BESP, which incorporates pricing practices, historical selling prices, the effect of market conditions as well as entity-specific factors. Estimated selling price is monitored and evaluated on a regular basis to ensure that changes in circumstances are accounted for in a timely manner. The Company recognizes milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract. As described above, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , received a milestone payment of $15 million , received $40 million milestone upon receipt of the J-code and is eligible to receive up to $25 million in an additional milestone payment on its commercial partner reaches a key sales milestone. In 2015, $30 million upfront payment was allocated between the license issued to Cephalon and obtaining and maintaining regulatory approvals and conducting post-approval clinical studies using the Company’s best estimate of selling price for each deliverable. The full $30 million was recognized as income in the first quarter of 2015, as the Company substantially completed its requirements for obtaining regulatory approval, which consisted of filing an NDA, on February 13, 2015, and the remaining obligations were estimated to require minimal effort. On December 7, 2015, the FDA approved Bendeka (50 mL bendamustine hydrochloride) marking the achievement of a milestone which entitled the Company to a $15 million payment which was received in January 2016. The Company received a $40 million milestone payment in November 2016 upon receipt of the unique J-code. Additionally, this event triggered an increase in the royalty rate from 20% to 25% of Bendeka net sales. Collaborative licensing and development revenue — The Company recognizes revenue from reimbursements received in connection with feasibility studies and development work for third parties when its contractual services are performed, provided collectability is reasonably assured. Its principal costs under these agreements include its personnel conducting research and development, and its allocated overhead, as well as the research and development performed by outside contractors or consultants. Upon termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are generally recognized in full. All such recognized revenues are included in collaborative licensing and development revenue in its statements of operations. The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event, and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the collaboration agreement. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value provisions of ASC 718, Compensation — Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees service periods, which are generally the vesting period of the equity awards. Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees . Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest. There are customary limitations on the sale or transfer of the stock. The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock-based awards to employees and directors is estimated using the Black-Scholes option valuation model, or Black-Scholes model. The Black-Scholes model requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. Earnings (Loss) Per Share Basic earnings (loss) per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings (loss) per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. The anti-dilutive common shares equivalents outstanding at December 31, 2016 , fiscal 2015, the transition period and fiscal 2014 were as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Series A — — — 888,099 Series B — — — 754,191 Series B-1 — — — 554,382 Series C — — — 654,896 Series C warrants — — — 56,078 Options 869,957 96,610 1,302,685 963,495 Total 869,957 96,610 1,302,685 3,871,141 The following table sets forth the computation for basic and diluted net income (loss) per share for December 31, 2016 , fiscal 2015, the transition period and fiscal 2014: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Numerator Numerator for basic and diluted earnings per share-net income (loss) $ 81,453 $ 2,571 $ (5,506 ) $ (19,643 ) Denominator Basic weighted average common shares outstanding 15,533,681 15,250,154 14,032,828 9,955,937 Dilutive effect of stock options 900,423 1,003,627 — — Diluted weighted average common shares outstanding 16,434,104 16,253,781 14,032,828 9,955,937 Basic net income (loss) per share Basic net income (loss) per share $ 5.24 $ 0.17 $ (0.39 ) $ (1.97 ) Diluted net income (loss) per share Diluted net income (loss) per share $ 4.96 $ 0.16 $ (0.39 ) $ (1.97 ) Recent Accounting Pronouncements Recent Accounting Pronouncements - Not Yet Adopted In May 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective for us on January 1, 2018, however early adoption is permitted any time after the original effective date, which for us is January 1, 2017. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments relate to when another party, along with the entity, is involved in providing a good or service to a customer. Topic 606 Revenue from Contracts with Customers requires an entity to determine whether the nature of its promise is to provide that good or service to the customer (i.e., the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is an agent). The amendments are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. The effective date and transition of these amendments is the same as the effective date and transition of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Public entities should apply the amendments in ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein (i.e., January 1, 2018, for a calendar year entity). We have not yet selected a transition method. We are currently evaluating the impact of ASU 2014-09 on our financial statements. In January 2016, the FASB issued ASU 2016-01, which revises the guidance in ASC 825-10, Recognition and Measurement of Financial Assets and Financial Liabilities, and provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The guidance is effective for reporting periods (interim and annual) beginning after December 15, 2017, for public companies. We are currently assessing the potential impact of this ASU on our financial position and results of operations. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of this new standard will increase assets and liabilities on our balance sheet when adopted. We are still fully assessing the overall impact of this ASU on our financial position and results of operations. In January 2017, the FASB issued guidance to simplify the measurement of goodwill. The guidance eliminates Step 2 from the goodwill impairment test. Instead, under the amendments in this guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The guidance also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. The guidance is effective for public business entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted for interim or annual goodwill impairment tests performed for testing dates after January 1, 2017. The guidance must be adopted on a prospective basis. We are currently evaluating the impact, if any, that the adoption of this guidance will have on our consolidated financial statements. In January 2017, the FASB issued guidance clarifying the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acqui

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: December 31, December 31, 2016 2015 Raw material $ 1,131 $ 8,687 Work in process 900 6,044 Finished products 708 311 $ 2,739 $ 15,042

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: December 31, December 31, Estimated Useful Life (years) 2016 2015 Furniture and equipment $ 1,121 $ 582 7 Office equipment 513 328 3 Equipment 2,059 1,182 7 Leasehold improvements 1,129 978 2 4,822 3,070 Less accumulated depreciation (1,506 ) (865 ) Property and equipment, net $ 3,316 $ 2,205 Depreciation expense amounted to $641 , $ 112 , $13 , and $104 , for fiscal 2016, fiscal 2015, the transition period, and fiscal 2014, respectively.

Balance Sheet Accounts

Balance Sheet Accounts	12 Months Ended
	Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts Prepaid and Other Current Assets Prepaid and other current assets consist of the following: December 31, December 31, 2016 2015 Advances to commercial manufacturers $ 7,600 $ 85 Prepaid FDA user fee 1,592 551 Prepaid insurance 135 218 Prepaid research and development 21 283 Prepaid income taxes 1,654 508 All other 355 220 Total Prepaid expenses and other current assets $ 11,357 $ 1,865 Accrued Expenses Accrued expenses consist of the following: December 31, December 31, 2016 2015 Accrued expenses Royalties due to Chiesi USA, Inc./The Medicines Company $ 1,030 $ 6,948 Royalties due to SciDose 8,038 1,637 Royalties due to Sandoz, Inc. — 1,249 Accrued research & development 3,528 1,784 Accrued professional fees 2,094 792 Accrued salary and other compensation 6,003 2,242 Accrued product costs 2,856 9,232 All other 1,688 521 Total Accrued expenses $ 25,237 $ 24,405 Deferred Revenue Deferred revenue consists of the following: December 31, December 31, 2016 2015 Deferred revenue Par Pharmaceutical, Inc. — 5,500 Par Pharmaceuticals Companies, Inc./Tech Transfer — 500 Deferred Revenue from Asset Sales (See Note 12) — 6,000 Total Deferred revenue $ — $ 6,000

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	Notes Payable Convertible Notes The Company entered into a Convertible Note and Warrant Purchase Agreement (the "Convertible Note Agreements"), pursuant to which it issued $9,663 of Convertible Notes (the "Convertible Notes") to existing preferred stockholders. The loan funding was completed in two tranches on August 2, 2012 and September 26, 2012, respectively. Holders of the Convertible Notes were entitled to cumulative interest at an annual rate of 6% . Such interest accrued daily and was cumulative from the respective date. In addition, the holders received warrants to purchase preferred stock, which accrued at a monthly rate of 2% of the principal amount until the completion of a Qualified Financing, as defined in the Convertible Note Agreement, or August 1, 2013, whichever was sooner. The Convertible Notes and associated accrued interest were due and payable on August 1, 2013, unless the Convertible Notes converted earlier. Conversion could occur, upon certain triggering events or the holder elects to convert. Principal and interest accrued shall convert into shares of preferred stock: a) upon the attainment of a Qualified Financing, or b) on August 1, 2013, whichever is sooner. Upon conversion pursuant to (a), the aggregate amount converted will be divided by the offering price of the Qualified Financing to arrive at the amount of preferred stock that will be issued. Upon conversion pursuant to (b), the aggregate amount converted will be divided by $1.82 to arrive at the amount of preferred stock that will be issued. The Series C Preferred Share financing (See Note 8) represented a Qualified Financing whereby the Convertible Notes for those participating investors converted to Series C Preferred Shares. The Convertible Notes agreement was structured such that a portion of the shares of the Company's Series A preferred stock, Series B preferred stock and Series B-1 preferred stock, collectively the "Special Conversion Preferred", held by a holder, that did not participate in the financing to the full extent of its pro-rata share of preferred stock ownership (a "Non-Fully Participating Holder"), was converted into shares of the Company's Common Stock, and any dividends accumulated to date were forfeited. The option for existing preferred stockholders to participate in the Convertible Notes expired on October 1, 2012. On October 2, 2012, 8,943,447 shares of preferred stock held by Non-Fully Participating Holders were converted into 1,395,226 shares of Common Stock. Warrants Prior to the initial public offering, the Company accounted for the warrants as liability instruments. The Company estimated the initial fair value of the 944,210 warrants to be $655 using a Probability-Weighted Expected Returns valuation model. At each reporting period, any changes to the fair value of the warrants were recorded in the statements of operations. As of December 31, 2016 , and December 31, 2015 , there were no warrants outstanding to purchase shares of common stock. The valuation model considered three scenarios. Two of the scenarios assumed a stockholder exit, either through sale, or dissolution. The third scenario assumed operations continue as a private company and no exit transaction occurred. The following assumptions were used in the valuation: exercise price of $1.82 ; implied stock price of $1.82 ; expected volatility of 64% ; expected dividend rate of 6% ; risk free interest rate of 0.83% and expiration date of six years . The following was a description of the key terms of the warrants per the warrant purchase agreement: • Exercise period — Exercisable, in whole or in part, during the six year term commencing on the earliest to occur of: (a) the consummation of a Qualified Financing, (b) immediately prior to the consummation of a Change of Control (but subject to and contingent upon such consummation of a Change of Control) and (c) the date one year after the Initial Closing or August 1, 2013. • Exercise Price — The purchase price for the Warrant Shares issuable was: (a) $1.82 , or (b) the offering price of a Qualified Financing should this occur prior to August 1, 2013. • No Rights as Stockholders — Prior to the exercise of the warrants, no holder of warrants (solely in its capacity as a holder of warrants) is entitled to any rights as a stockholder of the Company, including, without limitation, the right to vote, receive notice of any meeting of stockholders or receive dividends, allotments or other distributions. In February 2014, proceeds in the amount of $21 were received from the exercise of Series C preferred stock warrants for 1,788 common shares. In addition, Redeemable Series C preferred stock warrants were net exercised for 32,286 shares common stock upon the closing of the initial public offering. Warrant Liability On February 18, 2014 , the initial public offering date, the estimated fair value of the Convertible Note warrant liability was $2,280 which resulted in a charge to other income and expense of $383 . The change in the value of the warrant liability was $0 , $0 , $0 and $573 for fiscal 2016, 2015, the transition period and fiscal 2014, respectively. Upon the completion of the qualified offering, the warrants became exercisable into Series C Preferred Shares. The increase in the fair value of the warrant liability was primarily attributable to the liquidation preference of the Series C Preferred Shares to receive 2 times the original investment upon a liquidation event under certain circumstances.

Shares Subject to Redemption _

Shares Subject to Redemption — Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2016
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount [Abstract]
Shares Subject to Redemption - Convertible Preferred Stock	Shares Subject to Redemption — Convertible Preferred Stock Series A Convertible preferred stock On March 8, 2007, the Company issued 20,237,911 shares of Series A Convertible preferred stock, par value $0.001 (the "Series A preferred stock"). The outstanding shares of the Series A preferred stock (as amended in connection with the issuance of the Series B preferred stock) is redeemable after August 11, 2013 at a redemption price per share equal to the Original Issue Price of $0.971 per share plus accrued but unpaid dividends. The outstanding Series A convertible preferred stock converted into 2,332,051 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series A preferred stock were recorded at their estimated fair value of $19,651 which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $180 . The fair value of the Series A preferred stock had been increased through periodic accretions using the interest method for dividends (see "Preferred Stock Dividends" below) so that the carrying value equals the redemption amount on the redemption date. The accumulated dividend through the closing date of the initial public offering on February 18, 2014 of the Series A preferred stock was $ 97 . Series B Convertible Preferred Stock On August 11, 2008, the Company issued 16,052,343 shares of Series B Convertible preferred stock, par value $0.001 (the "Series B preferred stock"). The Series B preferred stock is redeemable as described above for the Series A preferred stock at a redemption price per share equal to the Original Issue Price of $1.82 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding Series B convertible preferred stock converted into 1,980,431 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series B preferred stock were recorded at their estimated fair value of $29,215 , which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $126 . The fair value of the Series B preferred stock had been increased through periodic accretions using the interest method so that the carrying value equals the redemption amount on the redemption date. The accumulated dividend through the closing date of the initial public offering on February 18, 2014 was $ 173 . Series B-1 Convertible Preferred Stock The Company consummated an offering of Series B-1 Convertible preferred stock, par value $0.001 (the "Series B-1 Preferred Stock") to its existing investors in two stages in February 2011 and July 2011. The Company issued an aggregate of 10,177,085 shares of Series B-1 preferred stock. The Series B-1 preferred stock is redeemable at a redemption price per share equal to the Original Issue Price of $1.82 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding series B-1 convertible preferred stock converted into 1,455,753 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series B-1 preferred stock were recorded at their estimated fair value of $17,522 which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $144 . On August 2, 2012, the Company entered into a Payoff and Exchange Agreement with an Officer/Director. The Company accepted a total of 549,451 shares of Series B-1 preferred stock in exchange for satisfaction of the principal amount of debt. The total number of outstanding shares of Series B-1 preferred stock was 9,331,374 as of September 30, 2013 . The fair value of the Series B preferred stock had been increased through periodic accretions using the interest method so that the carrying value equals the redemption amount on the redemption date. The accumulated dividend through the closing date of the initial public offering on February 18, 2014 of the Series B-1 preferred stock was $125 . Series C Convertible Preferred Stock The Company consummated an offering of Series C Convertible preferred stock, par value $0.001 (the "Series C preferred stock") on April 11, 2013. The Company issued an aggregate of 11,023,232 shares of Series C preferred stock. The Series C preferred stock is redeemable at a redemption price per share equal to the Original Issue Price of $1.82 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding series C convertible preferred stock converted into 1,719,693 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series C preferred stock were recorded at their estimated fair value of $20,062 which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $167 . The fair value of the Series C preferred stock had been increased through periodic accretions using the interest method so that the carrying value equals the redemption amount on the redemption date. The accumulated dividend through closing date of the initial public offering on February 18, 2014 of the Series C preferred stock was $139 .

Common Stock and Stock-Based Co

Common Stock and Stock-Based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock and Stock-Based Compensation	Common Stock and Stock-Based Compensation On August 9, 2016, the Company announced a share repurchase program approved by the Company’s board of directors authorizing the repurchase of up to $75.0 million of the Company’s common stock (the “Share Repurchase Program”). Under the Share Repurchase Program, the Company is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The Share Repurchase Program has no time limit and may be suspended or discontinued completely at any time. The specific timing and amount of repurchases will vary based on available capital resources and other financial and operational performance, market conditions, securities law limitations, and other factors. The repurchases will be made using the Company's cash resources. In any period, cash used in financing activities related to shares repurchased may differ from the comparable change in stockholders' equity, reflecting timing differences between the recognition of share repurchase transactions and their settlement for cash. We repurchased the following shares of common stock with cash resources during the year ended December 31, 2016 : Year Ended December 31, 2016 Shares of common stock repurchased 566,838 Value of common stock repurchased $ 37,003 In December 2007, the Company's board of directors approved the 2007 Incentive Compensation Plan (the "2007 Plan") enabling the Company to grant multiple stock based awards to employees, directors and consultants, the most common being stock options and restricted stock awards. In November 2013, the Company's board of directors approved the 2014 Equity Incentive Plan (the "2014 Plan") which became effective on February 11, 2014. The 2007 Plan was terminated upon the effectiveness of the 2014 Plan and all shares available for issuance under the 2007 Plan were made available under the 2014 Plan. The 2014 Plan provides for the awards of incentive stock options, non-qualified stock options, restricted stock, restricted stock units and other stock-based awards. Awards generally vest equally over a period of four years from grant date. Vesting is accelerated under a change in control of the Company or in the event of death or disability to the recipient. In the event of termination, any unvested shares or options are forfeited. At the Company's annual meeting of stockholders held on August 4, 2015, the stockholders approved an amendment to the 2014 Plan to, among other things, increase the number of shares of common stock authorized for issuance thereunder by 500,000 shares. After accounting for such increase, and as of such amendment, the Company has reserved and made available 2,106,545 shares of common stock for issuance under the 2014 Plan. During the quarter ended June 30, 2016 the Company entered into an agreement with Jay Moorin and Alain Schreiber, M.D., in connection with their resignations from the Company’s board of directors, which resulted in a stock option modification. Under this agreement the Company reversed $319 in previously recognized expense for unvested options and recorded $160 in Selling , general and administrative expense in the consolidated statements of operations for the year ended December 31, 2016 related to the acceleration of unvested options. The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended 2016 2015 2014 2014 Risk-free interest rate 0.94% - 2.34% 1.42% - 2.09% 2.11% - 2.16% 1.77% - 2.16% Volatility 30.95% - 32.36% 28.4% - 32.9% 39.45% 33.64% - 64.00% Expected term (in years) 5.04-7.0 years 5.5-7.0 years 6.59 - 10.00 years 6.07 - 9.39 years Expected dividend yield 0.0% 0.0% 0.0% 0.0% The Company recognized share-based compensation in its statements of operations for the year ended December 31, 2016 , fiscal 2015, the transition period, and fiscal 2014 as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Selling, general and administrative $ 7,073 $ 2,780 $ 144 $ 303 Research and development 2,695 1,271 140 303 Total $ 9,768 $ 4,051 $ 284 $ 606 The following table is a summary of the Company's stock options issued to employees, directors and consultants (amounts in thousands except per share amounts): Number of Stock Option Shares Weighted Average Exercise Price Non- Exercisable Exercisable Outstanding at September 30, 2014 1,308,993 $ 8.16 712,901 596,092 Granted 29,000 12.61 Exercised (4,513 ) 7.62 Forfeited or expired (11,310 ) Outstanding at December 31, 2014 1,322,170 $ 8.29 710,486 611,684 Granted 773,458 48.65 Exercised (211,190 ) 7.06 Forfeited or expired (39,596 ) Outstanding at December 31, 2015 1,844,842 $ 25.16 1,176,140 668,702 Granted 792,500 81.61 Exercised (214,194 ) 16.94 Forfeited or expired (98,230 ) Outstanding at December 31, 2016 2,324,918 $ 44.53 1,281,208 1,043,710 The weighted-average grant-date fair value of options granted during the year ended December 31, 2016 , fiscal 2015 , the transition period and fiscal 2014 was $27.79 , $15.92 , $6.73 and $4.61 , respectively. As of December 31, 2016 , there was $15,476 of unrecognized compensation cost, which will be expensed over the next 4 fiscal years. The total intrinsic value of options exercised during the year ended December 31, 2016 was $11,521 . The weighted average contractual terms of options outstanding as of December 31, 2016 , 2015 , 2014 and September 30, 2014 was 7.0 , 7.5 , 7.5 and 7.5 years, respectively. The aggregate pre-tax intrinsic value of options outstanding as of December 31, 2016 , 2015 , 2014 and September 30, 2014 was $59.2 million , $54.7 million , $9.6 million and $5.9 million , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of our benefit from (provision for) income taxes is as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Current: Federal $ (1,175 ) $ — $ — $ — State (919 ) (3 ) 1,059 1,295 $ (2,094 ) $ (3 ) $ 1,059 $ 1,295 Deferred: Federal 29,553 — — — State 567 — — — $ 30,120 $ — $ — $ — Benefit from (provision for) income taxes $ 28,026 $ (3 ) $ 1,059 $ 1,295 The table below provides reconciliation between the statutory federal income tax rate and the effective rate of income tax expense for each of the periods shown as follows. For periods with a loss before benefit for income taxes, favorable tax items result in an increase in the effective tax rate, while unfavorable tax items result in a decrease in the effective tax rate. For periods with income before provision for income taxes, favorable tax items result in an decrease in the effective tax rate, while, unfavorable tax items result in an increase in the effective tax rate. Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Federal statutory tax rate 35 % 34 % 34 % 34 % State income taxes, net of federal benefit 3 % — % 16 % 7 % Tax benefit on stock option exercises (7 )% — % — % — % Tax credits (3 )% (10 )% (3 )% (1 )% Other (1 )% 1 % — % (1 )% Change in valuation allowance (79 )% (25 )% (31 )% (32 )% Effective tax rate (52 )% — % 16 % 7 % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets were as follows: December 31, 2016 2015 Deferred tax assets Net operating loss carryforward $ 17,700 $ 30,837 Stock based compensation 5,185 2,100 Research and development tax credit carryforwards 4,993 2,790 Accrued bonus and other employee related expenses 1,946 741 Prepaid R&D expenses 1,643 1,884 Other 285 254 Total deferred tax assets 31,752 38,606 Deferred tax liabilities Intangible assets 2,944 — Prepaid expenses 80 81 Fixed assets 78 — Other 7 7 Total deferred tax liabilities 3,109 88 Valuation allowance — (38,518 ) Net deferred tax assets $ 28,643 $ — In the year ended December 31, 2016 we released a previously carried tax valuation allowance on our net deferred tax assets including net operating loss carryforwards and the tax benefit related to the exercises of stock options. Our decision to remove the valuation allowance on the Company's net deferred tax assets considered our significant income in 2016 which translated to our becoming a tax payer in 2016 and our outlook on prospective earnings and taxable income driven by Bendeka royalty and milestone revenues. As of December 31, 2016, the Company had federal and state net operating loss carryforwards of approximately $50,060 and $3,435 . The Company also had a federal and state research and development tax credit carryforwards of approximately $6,550 and $4 , respectively. The net operating loss and tax credit carryforwards will expire at various times through 2035. Section 382 of the Internal Revenue Code generally requires a corporation to limit the amount of its income in future years that can be offset by historic losses, i.e. net operating loss (NOL) carryforwards and certain built-in losses, after a corporation has undergone an ownership change. The Company is subject to a Section 382 limitation which will not materially affect the usage of the Company's tax losses and tax credits. In July 2006, the Financial Accounting Standards Board (“FASB”) issued ASC 740-10, Uncertainty in Income Taxes, which defines the threshold for recognizing the benefits of tax-return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities. This statement also requires explicit disclosure requirements about a Company’s uncertainties related to their income tax position, including a detailed roll forward of tax benefits taken that do not qualify for financial statement recognition. There are no such amounts recorded due to the adoption of the tax standard. The Company files income tax returns in the U.S. federal jurisdiction and several states. Given that the company has incurred tax losses since its inception, all of the Company’s tax years are effectively open to examination. The Company has no amount recorded for any unrecognized tax benefits as of December 31, 2016. The Company regularly evaluates its tax positions for additional unrecognized tax benefits and associated interest and penalties, if applicable. There are many factors that are considered when evaluating these tax positions including: interpretation of tax laws, recent tax litigation on a position, past audit or examination history, and subjective estimates and assumptions. The Company received approval to sell a portion of the Company's New Jersey net operating losses and tax credits as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology firms with unused net operating loss carryovers and unused research and development credits are allowed to sell these benefits to other firms. The Company has participated in the Technology Business Tax Certificate Program since 2009. The most recent sales are detailed below: During the three months ended December 31, 2014 the Company sold New Jersey state net operating loss (NJ NOL) carry forwards and tax credits totaling $12,588 and $15 , respectively for net proceeds of $1,059 which is reflected as a tax benefit in the transition period. During the year ended September 30, 2014, the Company sold New Jersey state net operating loss (NJ NOL) carry forwards and tax credits totaling $25,389 and $177 , respectively for net proceeds of $1,295 which is reflected as a tax benefit in fiscal year 2014. There were no sales of net operating losses during fiscal 2016 and 2015.

License Agreements of Developme

License Agreements of Development and Commercialization Rights	12 Months Ended
	Dec. 31, 2016
Research and Development [Abstract]
License Agreements of Development and Commercialization Rights	License Agreements of Development and Commercialization Rights Development On February 13, 2015, the Company submitted a New Drug Application or NDA to the FDA for Bendeka, which was approved by the FDA on December 7, 2015. Also, on February 13, 2015, the Company entered into the Cephalon License for U.S. and Canadian rights to Bendeka for treatment of patients with CLL and patients with NHL. Pursuant to the terms of the Cephalon License, Cephalon will be responsible for all U.S. commercial activities for the product including promotion and distribution, and the Company is responsible for obtaining and maintaining all regulatory approvals and conducting post-approval clinical studies. Additionally, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , in January 2016, received a $15 million milestone payment related to the FDA approval of Bendeka in December 2015, received $40 million related to the receipt of the J-code for Bendeka and is currently eligible to receive up to $25 million in an additional sales-based milestone payment. In addition, the Company was entitled to receive royalty payments of 20% of net sales of the product which increased to 25% on receipt of the J-code in November 2016. In connection with the Cephalon License, the Company has entered into a supply agreement with Cephalon, pursuant to which the Company is responsible for supplying product to Cephalon. On October 13, 2015, the Company entered into the Teikoku Agreement to market, sell and distribute Non-Alcohol Docetaxel Injection, an investigational product intended for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. The NDA for Non-Alcohol Docetaxel Injection for these indications was approved by the FDA on December 22, 2015. Under the terms of the agreement, the Company paid an upfront cash payment upon executing the agreement which was expensed and is included in research and development in the consolidated statements of operation for the year ended December 31, 2015 and an additional payment of $4,850 we capitalized (See Note 14. Acquisitions) upon FDA approval and NDA transfer to Eagle, which occurred in January 2016, and double-digit royalties on gross profits. The Company has entered into several product development agreements with development partners whereby the Company acquired the exclusive rights in the United States and, in most cases, worldwide rights to a total of thirty-three products for ten years following first commercial sale of each product. The Company will share varying percentages of the profits after, in most cases, recapturing development, legal and certain operating costs, from the sales of the products with the development partners if the products are commercialized. The Company expenses these costs as incurred. Commercialization Rights In May 2008, the Company entered into a collaborative product development agreement with a Branded product company, whereby the Company has agreed to develop a product for the Brand Company. Under the terms of the agreement, the Brand Company acquired the exclusive worldwide rights to market the product for ten years following approval. The Company will receive a royalty on net sales of the product, dependent upon the achievement of certain goals. In addition, the Company received $750 upon signing which was non-refundable and recorded as revenue in the year it was received and it will receive milestones of up to $13,000 upon the achievement of certain goals. The Brand Company is also required to pay all out of pocket costs related to the project and also made payments to the Company totaling $2,000 for the development of the product, payable at $200 per month commencing in April 2008. In July 2013, an arbitration settlement between the two companies was reached. The Company then terminated the contract; therefore, no additional revenues will be recognized.

Asset Sales

Asset Sales	12 Months Ended
	Dec. 31, 2016
Deferred Revenue Disclosure [Abstract]
Asset Sales	Asset Sales On March 28, 2012, the Company entered into an Asset Purchase Agreement (the “Hikma APA”) with Hikma Pharmaceutical Co. LTD, or Hikma. Under the terms of the agreement, Hikma acquired exclusive U.S. rights to market diclofenac-misoprostol following regulatory approval. The Company received $3,500 upon signing the Hikma APA. This amount was included in deferred revenue until FDA approval, since it was otherwise refundable. In addition, the Company was entitled to receive another $1,000 upon regulatory approval, validation batch manufacturing with inventory released for launch, and sufficient launch inventory. Before approval, this approval milestone was to be reduced for each generic competitor that received regulatory approval (excluding an "authorized generic" version of the Brand Product); however, the milestone was not to be reduced to an amount less than $500 . The Company was to receive a royalty on Net Profits of the product for a period of ten years from the date of the first commercial sale of the product, with the royalty percentage varying depending upon certain events and competition. On June 24, 2013, Hikma filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging that the Company (a) breached the Hikma APA by failing to refund the purchase price following Hikma's purported termination of the Hikma APA as a result of the Company failing to receive timely ANDA approval, and (b) intentionally failed to disclose alleged manufacturing product defects to Hikma. The Company believed that it did not fail to receive timely ANDA approval and therefore that Hikma was not entitled to (a) terminate the Hikma APA or (b) receive a refund of the purchase price. The Company also believed that it did not intentionally fail to disclose alleged manufacturing product defects to Hikma. If Hikma had prevailed on its claims, the Company could have been required to return the $3,500 purchase price plus interest, as well as other damages. The Company could not estimate the possible loss or range of loss related to the Hikma litigation beyond the $3,500 purchase price. On March 14, 2014, the Company received FDA approval of our Abbreviated New Drug Application for diclofenac-misoprostol tablets. The Company had not yet recognized the $3,500 as revenue since it was required to submit additional data to the FDA. In May 2014, under a CBE-30 supplement, the Company submitted additional data to the FDA with respect to manufacturing procedures of the product and achieved final approval in June 2014. On June 30, 2014, the Company had recognized the $3,500 purchase price as revenue in other revenue as it had received FDA approval and subsequently complied with all FDA requirements. Pursuant to the in-license agreement for diclofenac-misoprostol, the Company estimated amounts due to the licensor. On August 8, 2014, the Company settled the lawsuit with Hikma related to the Diclofenac Asset Purchase Agreement. Pursuant to the terms of the settlement the Company retained ownership of diclofenac-misoprostol including the rights to launch and commercialize the Product, and the Company will pay to Hikma a percentage of Net Profits after recovery of certain of the Company's expenses. During fiscal year 2010 and 2011, the Company divested another non-core product and received proceeds of $6,500 , comprised of $5,500 as a signing milestone which is recorded in deferred revenues and $500 for the initiation of Tech Transfer of which $250 remains in deferred revenues and a second payment of $500 for the completion of the Tech Transfer of which $250 remains in deferred revenues. Under the terms of this agreement, the licensor must obtain all of the following milestones in order for the Company to earn the revenues. These milestones are a) the receipt of an approval letter from the FDA, b) acknowledgment from the FDA that no further clinical studies will be needed and c) an approval letter from the FDA. The Company, through various requests for information, was informed by the licensor in 2016 that it had voluntarily withdrawn the filing of the product application from the FDA in a prior year. Under the terms of the agreement, the milestones required to earn the $6,000 previously included in deferred revenue all related to the filing. The voluntary withdrawal of the filing by the licensor relieved the Company of further obligation with regard to performance under the milestones. Accordingly, during the quarter ended March 31, 2016, the Company recognized the $6,000 as license and other income. See Note 6 for a summary of Deferred Revenue related to the Asset Sales. On March 29, 2016, the Company entered into the Diclofenac Asset Purchase Agreement pursuant to which the Company sold certain intellectual property related to diclofenac-misoprostol in the United States. In consideration of the assets and rights sold under the Diclofenac Asset Purchase Agreement, the Company received a one-time payment at closing of $1.75 million , which was recognized as a gain in the first quarter of 2016. In consideration of the rights granted under the Diclofenac Asset Purchase Agreement, the purchaser will pay the Company a 25% royalty on net profits of diclofenac-misoprostol in the territory for five years from the date of sale. The Company may continue to market diclofenac-misoprostol until such time that the purchaser is able to launch.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments At December 31, 2016 , the Company has purchase obligations in the amount of $16,512 which represent the contractual commitments under Contract Manufacturing and Supply Agreements with suppliers. The obligation under the supply agreement is primarily for finished product, inventory, and research and development. The Company leases its office space under a lease agreement that expires on June 30, 2020 . Rental expense was $634 , $514 , $68 , and $277 for fiscal 2016, fiscal 2015, the transition period and fiscal 2014, respectively. The remaining future lease payments under the operating lease are $1,973 as of December 31, 2016 , payable monthly through June 30, 2020 as follows: The Company is obligated to pay Spectrum Pharmaceuticals, Inc. $ 4,530 , which represents the base fee from the co-promotion agreement entered into on November 4, 2015 with an 18 month term. Total 2017 2018 2019 2020 2021 Beyond Operating lease obligations $ 1,973 564 564 564 281 — — Purchase obligations $ 16,512 16,512 — — — — — Spectrum base fee $ 4,530 4,530 — — — — —

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of Docetaxel-Injection, Non-Alcohol Formula On October 13, 2015, the Company entered into the Teikoku Agreement with Teikoku to market, sell and distribute Non-Alcohol Docetaxel Injection, an investigational product intended for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. The NDA for Non-Alcohol Docetaxel Injection for these indications was approved by the FDA on December 22, 2015. Under the terms of the agreement, the Company paid $4,850 upon FDA approval and NDA transfer to the Company, which occurred on January 12, 2016. The Company will also pay 25% royalties on future gross profits to Teikoku. The Company accounted for the transaction as a purchase of a business in 2016, in accordance with ASC 805 Business Combinations . The Company has measured the fair value of the future royalty payment using its own assumptions of future profitability of Non-Alcohol Docetaxel Injection. Acquisition contingent consideration is measured at fair value on a recurring basis using unobservable inputs; which accordingly represents a Level 3 measurement within the fair value hierarchy. Any change in fair value of the contingent consideration subsequent to the acquisition date is recognized in operating income within the condensed statement of operations. The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability since acquisition through December 31, 2016 which was recorded in selling, general and administrative expense in the condensed statements of operations: Opening Balance January 12, 2016 $ 6,370 Changes in fair value 856 Payment of contingent consideration (286 ) Closing Balance December 31, 2016 $ 6,940 Total consideration of $11,220 , which is comprised of the $4,850 cash paid on FDA approval and NDA transfer to the Company and the fair value of contingent consideration has been attributed to the intangible asset for Non-Alcohol Docetaxel Injection product rights. The results of operations related to Docetaxel Non-Alcohol Injection have been included in the statements of operations from the date of acquisition. Pro forma results of operations have not been presented because the effect of Docetaxel Non-Alcohol Injection was not material. The Company recorded product sales of Non-Alcohol Docetaxel Injection of $3,912 and a net loss of $9,422 in the twelve months ended December 31, 2016. The Company did not incur any significant acquisition related costs in connection with the Non-Alcohol Docetaxel Injection acquisition. Eagle Biologics Acquisition On November 16, 2016 the Company entered into an agreement to acquire Arsia Therapeutics (“Arsia”), an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how and subsequently renamed the subsidiary Eagle Biologics, Inc. ("Eagle Biologics"). Under the terms of the stock purchase agreement, we paid approximately $27.2 million in cash and 40,200 shares of Eagle common stock worth $3.0 million at closing. We also agreed to pay up to $48 million in additional payments upon the completion of certain milestones, for aggregate potential payments of $78 million . As part of the agreement, Eagle Biologics founders and Massachusetts Institute of Technology professors, Dr. Robert Langer and Dr. Alexander Klibanov, as well as other key members of the Eagle Biologics team, entered into agreements to work with Eagle to develop new formulations and solve delivery challenges in the large molecules space. The acquisition was accounted for as a business combination in accordance with ASC 805 which requires the assets acquired and liabilities assumed from Eagle Biologics were recorded as the acquisition date at their respective fair values. Eagle Biologics’ results of operations are included in the financial statements from the date of acquisition. For the year ended December 31, 2016, the Company has recognized revenue and net loss for Eagle Biologics subsequent to the closing on November 16, 2016, in the amount of $0.04 million and $0.08 million respectively. Eagle Biologics’ platform technology enables subcutaneous administration of high-dose biologics through improved formulation. Eagle Biologics has developed early-stage partnerships with major pharmaceutical companies to apply its technology to their biosimilar molecules, create subcutaneous versions of currently-marketed IV products and produce high-concentration formulations of clinical candidates. In addition to acquiring the technology platform, the Company plans to establish a Biologics Innovation Center in Kendall Square in Cambridge, Massachusetts. The following table summarizes the consideration transferred to acquire Eagle Biologics at the date of acquisition: The aggregate consideration consisted of: Preliminary fair value Cash consideration paid $ 27,209 Common stock issued (i) 3,046 Fair value of contingent consideration payable to seller(long term) (ii) 16,100 Total consideration $ 46,355 The following table summarizes the preliminary estimated fair values of assets acquired and liabilities assumed: Estimated fair value of assets acquired: Cash and cash equivalents $ 349 Accounts receivable 8 Prepaid expenses and other current assets 55 Property and equipment 162 Developed technology (iii) 8,100 Total identifiable assets 8,674 Estimated fair value of liabilities assumed: Accounts payable 191 Deferred income tax liability, net (iv) 1,473 Accrued expenses 398 Total liabilities assumed 2,062 Net assets acquired 6,612 Goodwill (v) 39,743 Total purchase price $ 46,355 (i) Under the stock purchase agreement, the number of common shares to be issued to the seller is equal to $2.7 million divided by the average of the closing day price per share for the thirty ( 30 ) trading days prior to the Closing Date. The average price of the common stock of 30 days prior to closing was $68.18 . Accordingly, the number of common stock to be issued to the seller was determined at 40,200 shares ( $2.7 million / $68.18 per share). The fair value of the common stock issued was determined based on the closing price of Eagle’s common stock on November 16, 2016. (ii) Under the stock purchase agreement, the contingent consideration includes four separate milestone payments which could aggregate to a total of $48 million payable to the seller upon achievement of certain clinical, regulatory and development milestones. These milestone payments are also subject to acceleration under certain circumstances described in the Purchase Agreement. In accordance with the provisions of ASC 805-30-25-5, each unit of contingent consideration is recognized at the acquisition date fair value. The acquisition date fair value of the contingent consideration is $16.1 million and has been classified as other liabilities within non-current liabilities. Such fair values are determined based on a probabilistic model with weights assigned on the likelihood of the Company achieving the clinical, regulatory and development milestones as well as acceleration event in the future. Each unit of contingent consideration is classified as a liability in the balance sheet and would be subsequently measured at fair value on each reporting date. Any future change in fair would be recognized in the statement of operations. (iii) The fair value of developed technology is determined primarily using the “cost method”. The cost method is based on the premise that a prudent investor would pay no more for an asset than its replacement or reproduction cost. The cost to replace the asset would include the cost of constructing a similar asset of equivalent utility at prices applicable at the time of the valuation analysis. The core technology intangible assets represent developed technology, which we refer to as excipient library, which may be used to improve current and future drug deliveries and have a finite useful lives. These assets are expected to be on a straight line basis over 5 years. These estimates will be adjusted accordingly if the final identifiable intangible asset valuation generates results, including corresponding useful lives and related amortization methods, that differ from the estimates, or if the above scope of intangible assets is modified. The final valuation is expected to be completed within 12 months from the completion of the acquisition. (iv) The net deferred income tax liability of $1.5 million primarily relates to the developed technology intangible assets, net of acquired net operating losses. (v) Goodwill is calculated as the difference between the acquisition date fair value of the consideration expected to be transferred and the values assigned to the assets acquired. Goodwill is not amortized but tested for impairment on an annual basis or when indications for impairment exists. Goodwill is not deductible for tax purposes. The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability since acquisition through December 31, 2016 which was recorded in selling, general and administrative expense in the condensed statements of operations: Opening Balance November 16, 2016 $ 16,100 Changes in fair value 101 Payment of contingent consideration — Closing Balance December 31, 2016 $ 16,201 Supplemental Pro forma financial information (unaudited) The following unaudited pro forma combined results of operations presents the Company’s financial results as if the acquisition of Eagle Biologics had been completed on January 1, 2015, with adjustments to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings which may result from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations that we would have recognized had we completed the transaction on January 1, 2015. Future results may vary significantly from the results in this pro forma information because of future events and transactions, as well as other factors. December 31, December 31, 2016 2015 Total revenue $ 193,050 $ 67,117 Net income 75,410 608 Pro forma net income per common share Basic $ 4.85 $ 0.04 Diluted $ 4.59 $ 0.04 The Company’s historical financial information was adjusted to give effect to the pro forma events that were directly attributable to the acquisition and factually supportable. The unaudited pro forma consolidated results include historical revenues and expenses of assets acquired in the acquisition with the following adjustments: • Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired; • Eliminate transaction costs and non-recurring charges directly related to the acquisition that were included in the historical results of operations for Eagle • Adjustment to recognize pro forma income tax based on income tax benefit on the amortization of intangible asset and recognize income tax expense on elimination of transaction costs using a marginal rate of 36% . Non-recurring transactions costs of $0.7 million related to the acquisition for the year ended December 31, 2016 are included in the consolidated statement of operations in selling, general and administrative expenses; these non-recurring transaction costs are excluded from the pro forma results in the above table.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Intangible Assets, Net The gross carrying amounts and net book value of our intangible assets are as follows: December 31, 2016 December 31, 2015 Useful Life (In Years) Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Docetaxel product rights 18 $ 11,220 $ (571 ) $ 10,649 $ — $ — $ — Ryanodex intangible 20 $ 15,000 $ (174 ) $ 14,826 Developed technology 5 $ 8,100 $ (203 ) $ 7,897 Total $ 34,320 $ (948 ) $ 33,372 $ — $ — $ — Amortization expense amounted to $948 , $0 , $0 , and $0 , for fiscal 2016, fiscal 2015, the transition period, and fiscal 2014, respectively. Based on definite-lived intangible assets recorded as of December 31, 2016 , and assuming that the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows: Estimated Amortization Expense Year Ending December 31, 2017 $ 2,846 2018 3,021 2019 3,143 2020 3,289 2021 3,246 All other 17,827 Total estimated amortization expense $ 33,372

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Medicines Company v. Eagle On February 2, 2016, The Medicines Company (“MDCO”) filed a complaint in the U.S. District Court for the District of New Jersey against the Company, SciDose LLC and TherDose Pharma Pvt. Ltd. (collectively the “Defendants”) relating to the Defendants’ work on a novel ready-to-use bivalirudin injection product (the “Bivalirudin Product”). The Complaint seeks statutory, contractual and equitable damages growing out of the Company’s filing for approval with the FDA an NDA for its RTU bivalirudin product. MDCO amended that complaint in April of 2016. The suit cites the May 7, 2008 License and Development Agreement (the “LDA”) between the Defendants and MDCO. In the lawsuit, MDCO alleges that the Company violated the terms of the LDA by, inter alia, developing the Bivalirudin Product, and that the Company's Bivalirudin Product infringes two patents that are jointly-owned by the Company and MDCO and violates an exclusive license that MDCO claims exists under the LDA. The Company filed a motion for summary judgment in October 2016. The Company continues to dispute the allegations made by MDCO and believes it has meritorious defenses to all of MDCO’s claims. Fact discovery is ongoing and closes in December 2017, with expert discovery closing in April 2018. Eagle v. Burwell On April 27, 2016, the Company filed an action in the U.S. District Court for the District of Columbia against the FDA and other federal defendants seeking an order requiring the FDA to grant us orphan drug exclusivity for Bendeka for the treatment of CLL and indolent B-cell NHL. The Company believes Bendeka is entitled to orphan drug exclusivity as a matter of law, and that the FDA’s decision violates federal law and is inconsistent with the holding of the U.S. District Court for the District of Columbia in Depomed Inc. v. U.S. Department of Health and Human Services. The parties have filed all substantive motions and pleadings and expect oral argument in mid 2017. Bauer v. Eagle On May 31, 2016, a federal securities class-action lawsuit (captioned Bauer v. Eagle Pharmaceuticals, Inc., et al., Case No. 16-cv-03091-JLL-JAD) was filed in the United States District Court for the District of New Jersey against the Company and the Company’s Chief Executive Officer. On August 1, 2016, plaintiffs Blake Bauer, Brent Kawamura and Guarang Patel (the "EGRX Investors Group"), filed a motion requesting the court to appoint the EGRX Investors Group as lead plaintiff and Kirby McInerney LLP as lead counsel. The motion was granted on September 9, 2016. On October 31, 2016, the EGRX Investors Group filed an amended class action complaint (the “Amended Complaint”) against the defendants, seeking compensatory damages and an award of costs and expenses, including attorneys’ and experts’ fees. The Amended Complaint alleges the defendants violated sections 10(b) and 20(a) of the Securities Exchange Act, as amended, by making false and/or misleading statements about, among other things: (a) EP-6101, (b) the Company’s expectations regarding the New Drug Application submitted for EP-6101, and (c) the Company’s business prospects. On December 16, 2016, defendants’ filed a motion to dismiss the Amended Complaint. Plaintiffs opposed that motion on January 30, 2017. Defendants’ filed their reply on March 1, 2017 and expect the court to decide the motion based on the papers unless otherwise notified by the court. In Re: Taxotere (Docetaxel) On February 1, 2017, the Company was named, among various other manufacturers, in three product liability suits that are consolidated in the U.S. District Court for the Eastern District of Louisiana as part of MDL 2740 (Civil Action No 2:17-cv-0085). The claims are for personal injuries allegedly arising out of the use of docetaxel. The Company believes that it has substantial meritorious defenses to these cases and maintains product liability insurance against such cases. However, litigation is inherently uncertain and the Company cannot predict the outcome of this litigation. These actions, if successful, or if our indemnification arrangements or insurance do not provide sufficient coverage against such claims, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Other In addition to the above proceedings, from time to time, the Company is and may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on the Company’s business, financial condition or results of operations. Furthermore, the Company believes that it has adequate reserves and adequate insurance coverage in respect of these claims; however, no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from such actions. Regardless of the outcome, litigation and claims can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Selected Quarterly Financial Da

Selected Quarterly Financial Data - Unaudited	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data - Unaudited	Selected Quarterly Financial Data - Unaudited A summary of quarterly financial information for fiscal 2016 and fiscal 2015 is as follows: For the Quarter Ended March 31, June 30, September 30, December 31, Total Fiscal Year 2016 2016 2016 2016 2016 (in thousands except share and per share amounts) Revenue $ 29,591 $ 40,918 $ 37,833 $ 81,140 $ 189,482 Income from operations $ (897 ) $ 13,656 $ 12,308 $ 28,284 $ 53,351 Net income attributable to common stockholders $ (896 ) $ 13,099 $ 11,952 $ 57,298 $ 81,453 Income per share attributable to common stockholders- basic $ (0.06 ) $ 0.84 $ 0.77 $ 3.75 $ 5.24 Income per share attributable to common stockholders- diluted $ (0.06 ) $ 0.80 $ 0.73 $ 3.52 $ 4.96 For the Quarter Ended March 31, June 30, September 30, December 31, Total Fiscal Year 2015 2015 2015 2015 2015 (in thousands except share and per share amounts) Revenue $ 36,309 $ 6,002 $ 5,736 $ 18,180 $ 66,227 Income (Loss) from operations $ 20,090 $ (8,335 ) $ (10,388 ) $ 1,193 $ 2,560 Net income (loss) attributable to common stockholders $ 19,697 $ (8,177 ) $ (10,167 ) $ 1,218 $ 2,571 Income (loss) per share attributable to common stockholders- basic $ 1.38 $ (0.53 ) $ (0.65 ) $ 0.08 $ 0.17 Income (loss) per share attributable to common stockholders- diluted $ 1.31 $ (0.53 ) $ (0.65 ) $ 0.07 $ 0.16

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 26, 2017, the Company entered into a Credit Agreement (the “Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent (“Agent”) and the lenders party thereto. The Credit Agreement provides for a three -year $50 million revolving credit facility (the “Credit Facility”), none of which was drawn at closing. The Credit Facility includes a $5 million letter of credit subfacility. The Company expects to use future loans under the Credit Facility, if any, for working capital needs and for general corporate purposes. Loans under the Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 2.50% to 3.00% per annum, based upon the total net leverage ratio (as defined in the Credit Agreement), or (b) the prime lending rate, plus an applicable margin ranging from 1.50% to 2.00% per annum, based upon the total net leverage ratio. The Company is required to pay a commitment fee on the unused portion of the Credit Facility at a rate ranging from 0.35% to 0.40% based upon the total net leverage ratio. The Company is permitted to terminate or reduce the revolving commitments of the lenders and to make voluntary prepayments at any time subject to break funding payments. The Company is not required to make mandatory prepayments of outstanding indebtedness under the Credit Agreement other than in the case that the aggregate amount of all outstanding loans and letters of credit issued under the Credit Facility exceed the aggregate commitment of all lenders under the Credit Facility. Under the terms of the Cephalon License, the Company is entitled to receive a $25 million milestone payment when Teva reaches $500 million in cumulative net sales. In the first quarter of 2017, this milestone has been achieved and we expect to record this as revenue, accordingly.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
Reclassifications	Reclassifications Certain reclassifications have been made to prior year amounts to conform with the current year presentation
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature. The Company, at times, maintains balances with financial institutions in excess of the FDIC limit.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company's financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and contingent consideration from acquisitions. The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximate their fair values due to their short term maturities. Contingent consideration is recorded at fair value.
Short Term Investments	Short Term Investments Investments consisted of U.S. Treasury securities that have an original maturity of greater than three months and typically less than 180 days. The Company's investments were classified as Level 1 and available-for-sale and are recorded at fair value, based upon quoted market prices. No gains or losses on investments are realized until the sale occurs or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Fair Value Measurements	Fair Value Measurements U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of interest-bearing cash and cash equivalents and short term investments are classified as Level 1 for all periods presented. The fair value of contingent consideration is classified as Level 3 for the period presented. The Company is required by U.S. GAAP to record certain assets and liabilities at fair value on a recurring basis. Company marks the value of its warrant liability to market and recognize the change in valuation in its statement of operations each reporting period. Determining the warrant liability to be recorded required the Company to develop estimates to be used in calculating the fair value of the warrant. Since these preferred stock warrants did not trade in an active securities market, the Company recognized a warrant liability and estimated the fair value of these warrants using a Probability-Weighted Expected Returns valuation model. Therefore, the warrant liability was considered a Level 3 measurement.
Intangible Assets	Intangible Assets The Company capitalizes and includes in intangible assets the costs of acquired product licenses and developed technology purchased individually or identified in a business combination. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization The Company amortizes its definite-lived intangible assets using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. We will evaluate the potential impairment of other intangible assets if events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Events giving rise to impairment are an inherent risk in our industry and many factors cannot be predicted. Factors that we consider in deciding when to perform an impairment review include significant changes in our forecasted projections for the asset or asset group for reasons including, but not limited to, significant under-performance of a product in relation to expectations, significant changes or planned changes in our use of the assets, significant negative industry or economic trends, and new or competing products that enter the marketplace. The impairment test is based on a comparison of the undiscounted cash flows expected to be generated from the use of the asset group and its eventual disposition to the carrying value of the asset group. If impairment is indicated, the asset is written down by the amount by which the carrying value of the asset exceeds the related fair value of the asset with the related impairment charge recognized within the statements of operations. We did not identify any impairment to our definite-lived intangible assets in the periods presented. With respect to determining an asset’s fair value and useful life, because this process involves management making certain estimates and because these estimates form the basis of the determination of whether or not an impairment charge should be recorded, these estimates are considered to be critical accounting estimates. Such impairment charges may be material to our results.
Goodwill	Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment model requires a two-step method for determining goodwill impairment. In the first step, we determine the fair value of our reporting units using an appropriate valuation methodology. If the net book value of a reporting unit exceeds its fair value, we would then perform the second step of the impairment test which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations. Any residual fair value is allocated to goodwill. An impairment charge is recognized only when the implied fair value of our reporting unit’s goodwill is less than its carrying amount. We did not identify any impairment to goodwill during the periods presented.
Acquisition-Related Contingent Consideration	Acquisition-Related Contingent Consideration Contingent consideration related to a business combination is recorded at the acquisition date at the estimated fair value of the contingent payments. The acquisition date fair value is measured based on the consideration expected to be transferred using probability-weighted assumptions and discounted back to present value. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. The fair value of the acquisition-related contingent consideration is re-measured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in the consolidated statements of operations.
Concentration of Major Customers and Vendors	Concentration of Major Customers and Vendors The Company is dependent on commercial partners to market and sell Argatroban and Bendeka. The Company's customers for Argatroban are its commercial and licensing partners, therefore, the Company's future revenues are highly dependent on these collaboration and distribution arrangements Currently, for Argatroban and Bendeka, the Company uses one vendor as its sole source supplier. Because of the unique equipment and process for manufacturing, transferring manufacturing activities to an alternate supplier would be a time consuming and costly endeavor, and there are only a limited number of manufacturers that are capable of performing this function for the Company.
Inventory	Inventory Inventory is recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in value is first recognized. In most instances, inventory is shipped from the Company's vendor directly to the Company's customers.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation is computed over the estimated useful lives of the assets utilizing the straight-line method. Leasehold improvements are being amortized over the shorter of their useful lives or the lease term.
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock The carrying value of redeemable convertible preferred stock was increased by periodic accretions, using the interest method so that the carrying amount would equal the redemption amount at the earliest redemption date.
Research and Development Expense	Research and Development Expense Costs incurred for research and product development, including costs incurred for technology in the development stage, are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Advance payments for goods or services that will be used for future research and development activities are capitalized as deferred cost and expensed as the related goods are delivered or services performed. Recoveries of previously recognized R&D expenses from third parties are recorded as a reduction to R&D expense in the period it becomes realizable.
Advertising and Marketing	Advertising and Marketing Advertising and marketing costs are expensed as incurred.
Income Taxes	Income Taxes We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. Since our inception, we have incurred substantial cumulative losses and through the third quarter of 2016 we recorded a full valuation allowance against our net deferred tax assets which was largely made up of our net operating loss carryforward. In the fourth quarter of 2016, the Company reversed the reserve on its net deferred tax asset (See Note 10 - Income Taxes). ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Revenue Recognition	Revenue Recognition Product revenue - The Company recognizes net revenue on sales to its commercial partners and to end users. In each instance, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered and collectability is reasonably assured. Revenue on sales to commercial partners relates to Argatroban and Bendeka. The Company’s commercial partners can return product within specified timeframes if the product does not meet certain inspection tests. Sales to our commercial partners are presented gross primarily because the Company is the primary obligor in the arrangement, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue on sales to end users for Non-Alcohol Docetaxel Injection, Ryanodex and diclofenac-misoprostol are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. The Company has a product returns policy on some of its products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. The Company's estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. The Company has terms on sales of Ryanodex by which the Company does not accept returns. The Company believes that the reserves it has established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amount for reserves to vary. Royalty Revenue — The Company recognizes revenue from license arrangements with its commercial partners' net sales of products. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collectability is reasonably assured. The Company's commercial partners are obligated to report their net product sales and the resulting royalty due to the Company within 25 days for Bendeka and 60 days for Argatroban from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial. License and other income — The Company analyzes each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. When a sale combines multiple elements upon performance of multiple services, the Company allocates revenue for transactions that include multiple elements to each unit of accounting which is deliverable or combination of deliverables under the arrangement that has stand-alone value to the counter-party based on its relative selling price, and recognizes revenue for each unit of accounting when the revenue recognition criteria have been met. The Company follows the selling price hierarchy as outlined in the guidance Revenue Recognition (ASC Topic 605) - Multiple-Deliverable Revenue Arrangements . The guidance provides a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence (“VSOE”), (ii) third-party evidence (“TPE”) if available and when VSOE is not available, and (iii) best estimate of the selling price (“BESP”) if neither VSOE nor TPE is available. The Company uses BESP to determine the stand-alone selling price for such deliverables. The Company has an established process for developing BESP, which incorporates pricing practices, historical selling prices, the effect of market conditions as well as entity-specific factors. Estimated selling price is monitored and evaluated on a regular basis to ensure that changes in circumstances are accounted for in a timely manner. The Company recognizes milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract. As described above, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , received a milestone payment of $15 million , received $40 million milestone upon receipt of the J-code and is eligible to receive up to $25 million in an additional milestone payment on its commercial partner reaches a key sales milestone. In 2015, $30 million upfront payment was allocated between the license issued to Cephalon and obtaining and maintaining regulatory approvals and conducting post-approval clinical studies using the Company’s best estimate of selling price for each deliverable. The full $30 million was recognized as income in the first quarter of 2015, as the Company substantially completed its requirements for obtaining regulatory approval, which consisted of filing an NDA, on February 13, 2015, and the remaining obligations were estimated to require minimal effort. On December 7, 2015, the FDA approved Bendeka (50 mL bendamustine hydrochloride) marking the achievement of a milestone which entitled the Company to a $15 million payment which was received in January 2016. The Company received a $40 million milestone payment in November 2016 upon receipt of the unique J-code. Additionally, this event triggered an increase in the royalty rate from 20% to 25% of Bendeka net sales. Collaborative licensing and development revenue — The Company recognizes revenue from reimbursements received in connection with feasibility studies and development work for third parties when its contractual services are performed, provided collectability is reasonably assured. Its principal costs under these agreements include its personnel conducting research and development, and its allocated overhead, as well as the research and development performed by outside contractors or consultants. Upon termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are generally recognized in full. All such recognized revenues are included in collaborative licensing and development revenue in its statements of operations. The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event, and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the collaboration agreement.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the fair value provisions of ASC 718, Compensation — Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees service periods, which are generally the vesting period of the equity awards. Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees . Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest. There are customary limitations on the sale or transfer of the stock. The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock-based awards to employees and directors is estimated using the Black-Scholes option valuation model, or Black-Scholes model. The Black-Scholes model requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Basic earnings (loss) per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings (loss) per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements - Not Yet Adopted In May 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective for us on January 1, 2018, however early adoption is permitted any time after the original effective date, which for us is January 1, 2017. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments relate to when another party, along with the entity, is involved in providing a good or service to a customer. Topic 606 Revenue from Contracts with Customers requires an entity to determine whether the nature of its promise is to provide that good or service to the customer (i.e., the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is an agent). The amendments are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. The effective date and transition of these amendments is the same as the effective date and transition of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Public entities should apply the amendments in ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein (i.e., January 1, 2018, for a calendar year entity). We have not yet selected a transition method. We are currently evaluating the impact of ASU 2014-09 on our financial statements. In January 2016, the FASB issued ASU 2016-01, which revises the guidance in ASC 825-10, Recognition and Measurement of Financial Assets and Financial Liabilities, and provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The guidance is effective for reporting periods (interim and annual) beginning after December 15, 2017, for public companies. We are currently assessing the potential impact of this ASU on our financial position and results of operations. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of this new standard will increase assets and liabilities on our balance sheet when adopted. We are still fully assessing the overall impact of this ASU on our financial position and results of operations. In January 2017, the FASB issued guidance to simplify the measurement of goodwill. The guidance eliminates Step 2 from the goodwill impairment test. Instead, under the amendments in this guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The guidance also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. The guidance is effective for public business entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted for interim or annual goodwill impairment tests performed for testing dates after January 1, 2017. The guidance must be adopted on a prospective basis. We are currently evaluating the impact, if any, that the adoption of this guidance will have on our consolidated financial statements. In January 2017, the FASB issued guidance clarifying the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The guidance provides a screen to determine when an integrated set of assets and activities is not a business, provides a framework to assist entities in evaluating whether both an input and substantive process are present, and narrows the definition of the term output. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The guidance must be adopted on a prospective basis. We are currently evaluating the impact, if any, that the adoption of this guidance will have on our consolidated financial statements. No other accounting standards or interpretations issued recently are expected to have a material impact on our financial statements. Recent Adopted Accounting Pronouncements In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. In 2016, we early adopted this ASU. With the adoption of this ASU, the Company continues to estimate forfeitures in the calculation of stock based compensation. In November 2015, the FASB issued ASU 2015-17, which revises the guidance in ASC 740, Income Taxes, to simplify the presentation of deferred income taxes and require that deferred tax liabilities and assets be classified as non-current in the statement of financial position. We adopted this standard in 2016. It did not have a material impact on our financial position or results of operations.

Transition Period (Tables)

Transition Period (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Comparative Financial Information	The following table provides certain unaudited comparative financial information for the same period of the prior year. Three Months Ended 2014 2013 (unaudited) Revenue: Product sales $ 1,506 $ 2,224 Royalty revenue 4,094 3,268 Total revenue 5,600 5,492 Operating expenses: Cost of product sales 1,782 2,670 Cost of royalty revenue 2,707 1,954 Research and development 3,986 2,589 Selling, general and administrative 3,690 1,344 Total operating expenses 12,165 8,557 Loss from operations (6,565 ) (3,065 ) Interest income 1 1 Interest expense (1 ) — Change in value of warrant liability — (191 ) Total other (expense) — (190 ) Loss before income tax benefit (6,565 ) (3,255 ) Income tax benefit 1,059 — Net Loss $ (5,506 ) $ (3,255 ) Less dividends on Series A, B, B-1 and C Convertible Preferred Stock — (1,132 ) Net loss attributable to common stockholders $ (5,506 ) $ (4,387 ) Loss per share attributable to common stockholders Basic and diluted $ (0.39 ) $ (1.44 ) Weighted average common shares outstanding Basic and diluted 14,032,828 3,048,131

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Net product sales, royalty and license revenues The Medicines Company/Chiesi USA, Inc. 4 % 14 % 36 % 45 % Sandoz, Inc. 5 % 5 % 55 % 53 % Cephalon, Inc. (Teva) 79 % 68 % — % — % Other 12 % 13 % 9 % 2 % 100 % 100 % 100 % 100 % December 31, December 31, 2016 2015 Accounts receivable The Medicines Company/Chiesi USA, Inc. 3 % 35 % Sandoz, Inc. 8 % — % Cephalon, Inc. (Teva) 74 % 57 % Other 15 % 8 % 100 % 100 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The anti-dilutive common shares equivalents outstanding at December 31, 2016 , fiscal 2015, the transition period and fiscal 2014 were as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Series A — — — 888,099 Series B — — — 754,191 Series B-1 — — — 554,382 Series C — — — 654,896 Series C warrants — — — 56,078 Options 869,957 96,610 1,302,685 963,495 Total 869,957 96,610 1,302,685 3,871,141
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation for basic and diluted net income (loss) per share for December 31, 2016 , fiscal 2015, the transition period and fiscal 2014: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Numerator Numerator for basic and diluted earnings per share-net income (loss) $ 81,453 $ 2,571 $ (5,506 ) $ (19,643 ) Denominator Basic weighted average common shares outstanding 15,533,681 15,250,154 14,032,828 9,955,937 Dilutive effect of stock options 900,423 1,003,627 — — Diluted weighted average common shares outstanding 16,434,104 16,253,781 14,032,828 9,955,937 Basic net income (loss) per share Basic net income (loss) per share $ 5.24 $ 0.17 $ (0.39 ) $ (1.97 ) Diluted net income (loss) per share Diluted net income (loss) per share $ 4.96 $ 0.16 $ (0.39 ) $ (1.97 )

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: December 31, December 31, 2016 2015 Raw material $ 1,131 $ 8,687 Work in process 900 6,044 Finished products 708 311 $ 2,739 $ 15,042

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment consists of the following: December 31, December 31, Estimated Useful Life (years) 2016 2015 Furniture and equipment $ 1,121 $ 582 7 Office equipment 513 328 3 Equipment 2,059 1,182 7 Leasehold improvements 1,129 978 2 4,822 3,070 Less accumulated depreciation (1,506 ) (865 ) Property and equipment, net $ 3,316 $ 2,205

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	12 Months Ended
	Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following: December 31, December 31, 2016 2015 Advances to commercial manufacturers $ 7,600 $ 85 Prepaid FDA user fee 1,592 551 Prepaid insurance 135 218 Prepaid research and development 21 283 Prepaid income taxes 1,654 508 All other 355 220 Total Prepaid expenses and other current assets $ 11,357 $ 1,865
Schedule of Accrued Expenses	Accrued expenses consist of the following: December 31, December 31, 2016 2015 Accrued expenses Royalties due to Chiesi USA, Inc./The Medicines Company $ 1,030 $ 6,948 Royalties due to SciDose 8,038 1,637 Royalties due to Sandoz, Inc. — 1,249 Accrued research & development 3,528 1,784 Accrued professional fees 2,094 792 Accrued salary and other compensation 6,003 2,242 Accrued product costs 2,856 9,232 All other 1,688 521 Total Accrued expenses $ 25,237 $ 24,405
Schedule of Deferred Revenue	Deferred revenue consists of the following: December 31, December 31, 2016 2015 Deferred revenue Par Pharmaceutical, Inc. — 5,500 Par Pharmaceuticals Companies, Inc./Tech Transfer — 500 Deferred Revenue from Asset Sales (See Note 12) — 6,000 Total Deferred revenue $ — $ 6,000

Common Stock and Stock-Based 31

Common Stock and Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Class of Treasury Stock	We repurchased the following shares of common stock with cash resources during the year ended December 31, 2016 : Year Ended December 31, 2016 Shares of common stock repurchased 566,838 Value of common stock repurchased $ 37,003
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended 2016 2015 2014 2014 Risk-free interest rate 0.94% - 2.34% 1.42% - 2.09% 2.11% - 2.16% 1.77% - 2.16% Volatility 30.95% - 32.36% 28.4% - 32.9% 39.45% 33.64% - 64.00% Expected term (in years) 5.04-7.0 years 5.5-7.0 years 6.59 - 10.00 years 6.07 - 9.39 years Expected dividend yield 0.0% 0.0% 0.0% 0.0%
Recognized Share-based Compensation in Statements of Operations	The Company recognized share-based compensation in its statements of operations for the year ended December 31, 2016 , fiscal 2015, the transition period, and fiscal 2014 as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Selling, general and administrative $ 7,073 $ 2,780 $ 144 $ 303 Research and development 2,695 1,271 140 303 Total $ 9,768 $ 4,051 $ 284 $ 606
Schedule of Stock Option Activity	The following table is a summary of the Company's stock options issued to employees, directors and consultants (amounts in thousands except per share amounts): Number of Stock Option Shares Weighted Average Exercise Price Non- Exercisable Exercisable Outstanding at September 30, 2014 1,308,993 $ 8.16 712,901 596,092 Granted 29,000 12.61 Exercised (4,513 ) 7.62 Forfeited or expired (11,310 ) Outstanding at December 31, 2014 1,322,170 $ 8.29 710,486 611,684 Granted 773,458 48.65 Exercised (211,190 ) 7.06 Forfeited or expired (39,596 ) Outstanding at December 31, 2015 1,844,842 $ 25.16 1,176,140 668,702 Granted 792,500 81.61 Exercised (214,194 ) 16.94 Forfeited or expired (98,230 ) Outstanding at December 31, 2016 2,324,918 $ 44.53 1,281,208 1,043,710

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The components of our benefit from (provision for) income taxes is as follows: Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Current: Federal $ (1,175 ) $ — $ — $ — State (919 ) (3 ) 1,059 1,295 $ (2,094 ) $ (3 ) $ 1,059 $ 1,295 Deferred: Federal 29,553 — — — State 567 — — — $ 30,120 $ — $ — $ — Benefit from (provision for) income taxes $ 28,026 $ (3 ) $ 1,059 $ 1,295
Schedule of Effective Income Tax Rate Reconciliation	The table below provides reconciliation between the statutory federal income tax rate and the effective rate of income tax expense for each of the periods shown as follows. For periods with a loss before benefit for income taxes, favorable tax items result in an increase in the effective tax rate, while unfavorable tax items result in a decrease in the effective tax rate. For periods with income before provision for income taxes, favorable tax items result in an decrease in the effective tax rate, while, unfavorable tax items result in an increase in the effective tax rate. Year Ended December 31, Year Ended December 31, Three Months Ended December 31, Year Ended September 30, 2016 2015 2014 2014 Federal statutory tax rate 35 % 34 % 34 % 34 % State income taxes, net of federal benefit 3 % — % 16 % 7 % Tax benefit on stock option exercises (7 )% — % — % — % Tax credits (3 )% (10 )% (3 )% (1 )% Other (1 )% 1 % — % (1 )% Change in valuation allowance (79 )% (25 )% (31 )% (32 )% Effective tax rate (52 )% — % 16 % 7 %
Schedule of Deferred Tax Assets and Liabilities	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets were as follows: December 31, 2016 2015 Deferred tax assets Net operating loss carryforward $ 17,700 $ 30,837 Stock based compensation 5,185 2,100 Research and development tax credit carryforwards 4,993 2,790 Accrued bonus and other employee related expenses 1,946 741 Prepaid R&D expenses 1,643 1,884 Other 285 254 Total deferred tax assets 31,752 38,606 Deferred tax liabilities Intangible assets 2,944 — Prepaid expenses 80 81 Fixed assets 78 — Other 7 7 Total deferred tax liabilities 3,109 88 Valuation allowance — (38,518 ) Net deferred tax assets $ 28,643 $ —

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Commitments	Total 2017 2018 2019 2020 2021 Beyond Operating lease obligations $ 1,973 564 564 564 281 — — Purchase obligations $ 16,512 16,512 — — — — — Spectrum base fee $ 4,530 4,530 — — — — —

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration	The following table summarizes the consideration transferred to acquire Eagle Biologics at the date of acquisition: The aggregate consideration consisted of: Preliminary fair value Cash consideration paid $ 27,209 Common stock issued (i) 3,046 Fair value of contingent consideration payable to seller(long term) (ii) 16,100 Total consideration $ 46,355 The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability since acquisition through December 31, 2016 which was recorded in selling, general and administrative expense in the condensed statements of operations: Opening Balance November 16, 2016 $ 16,100 Changes in fair value 101 Payment of contingent consideration — Closing Balance December 31, 2016 $ 16,201 The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability since acquisition through December 31, 2016 which was recorded in selling, general and administrative expense in the condensed statements of operations: Opening Balance January 12, 2016 $ 6,370 Changes in fair value 856 Payment of contingent consideration (286 ) Closing Balance December 31, 2016 $ 6,940
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary estimated fair values of assets acquired and liabilities assumed: Estimated fair value of assets acquired: Cash and cash equivalents $ 349 Accounts receivable 8 Prepaid expenses and other current assets 55 Property and equipment 162 Developed technology (iii) 8,100 Total identifiable assets 8,674 Estimated fair value of liabilities assumed: Accounts payable 191 Deferred income tax liability, net (iv) 1,473 Accrued expenses 398 Total liabilities assumed 2,062 Net assets acquired 6,612 Goodwill (v) 39,743 Total purchase price $ 46,355 (i) Under the stock purchase agreement, the number of common shares to be issued to the seller is equal to $2.7 million divided by the average of the closing day price per share for the thirty ( 30 ) trading days prior to the Closing Date. The average price of the common stock of 30 days prior to closing was $68.18 . Accordingly, the number of common stock to be issued to the seller was determined at 40,200 shares ( $2.7 million / $68.18 per share). The fair value of the common stock issued was determined based on the closing price of Eagle’s common stock on November 16, 2016. (ii) Under the stock purchase agreement, the contingent consideration includes four separate milestone payments which could aggregate to a total of $48 million payable to the seller upon achievement of certain clinical, regulatory and development milestones. These milestone payments are also subject to acceleration under certain circumstances described in the Purchase Agreement. In accordance with the provisions of ASC 805-30-25-5, each unit of contingent consideration is recognized at the acquisition date fair value. The acquisition date fair value of the contingent consideration is $16.1 million and has been classified as other liabilities within non-current liabilities. Such fair values are determined based on a probabilistic model with weights assigned on the likelihood of the Company achieving the clinical, regulatory and development milestones as well as acceleration event in the future. Each unit of contingent consideration is classified as a liability in the balance sheet and would be subsequently measured at fair value on each reporting date. Any future change in fair would be recognized in the statement of operations. (iii) The fair value of developed technology is determined primarily using the “cost method”. The cost method is based on the premise that a prudent investor would pay no more for an asset than its replacement or reproduction cost. The cost to replace the asset would include the cost of constructing a similar asset of equivalent utility at prices applicable at the time of the valuation analysis. The core technology intangible assets represent developed technology, which we refer to as excipient library, which may be used to improve current and future drug deliveries and have a finite useful lives. These assets are expected to be on a straight line basis over 5 years. These estimates will be adjusted accordingly if the final identifiable intangible asset valuation generates results, including corresponding useful lives and related amortization methods, that differ from the estimates, or if the above scope of intangible assets is modified. The final valuation is expected to be completed within 12 months from the completion of the acquisition. (iv) The net deferred income tax liability of $1.5 million primarily relates to the developed technology intangible assets, net of acquired net operating losses. (v) Goodwill is calculated as the difference between the acquisition date fair value of the consideration expected to be transferred and the values assigned to the assets acquired. Goodwill is not amortized but tested for impairment on an annual basis or when indications for impairment exists. Goodwill is not deductible for tax purposes.
Business Acquisition, Pro Forma Information	December 31, December 31, 2016 2015 Total revenue $ 193,050 $ 67,117 Net income 75,410 608 Pro forma net income per common share Basic $ 4.85 $ 0.04 Diluted $ 4.59 $ 0.04

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The gross carrying amounts and net book value of our intangible assets are as follows: December 31, 2016 December 31, 2015 Useful Life (In Years) Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Docetaxel product rights 18 $ 11,220 $ (571 ) $ 10,649 $ — $ — $ — Ryanodex intangible 20 $ 15,000 $ (174 ) $ 14,826 Developed technology 5 $ 8,100 $ (203 ) $ 7,897 Total $ 34,320 $ (948 ) $ 33,372 $ — $ — $ —
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Based on definite-lived intangible assets recorded as of December 31, 2016 , and assuming that the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows: Estimated Amortization Expense Year Ending December 31, 2017 $ 2,846 2018 3,021 2019 3,143 2020 3,289 2021 3,246 All other 17,827 Total estimated amortization expense $ 33,372

Selected Quarterly Financial 36

Selected Quarterly Financial Data - Unaudited (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data	A summary of quarterly financial information for fiscal 2016 and fiscal 2015 is as follows: For the Quarter Ended March 31, June 30, September 30, December 31, Total Fiscal Year 2016 2016 2016 2016 2016 (in thousands except share and per share amounts) Revenue $ 29,591 $ 40,918 $ 37,833 $ 81,140 $ 189,482 Income from operations $ (897 ) $ 13,656 $ 12,308 $ 28,284 $ 53,351 Net income attributable to common stockholders $ (896 ) $ 13,099 $ 11,952 $ 57,298 $ 81,453 Income per share attributable to common stockholders- basic $ (0.06 ) $ 0.84 $ 0.77 $ 3.75 $ 5.24 Income per share attributable to common stockholders- diluted $ (0.06 ) $ 0.80 $ 0.73 $ 3.52 $ 4.96 For the Quarter Ended March 31, June 30, September 30, December 31, Total Fiscal Year 2015 2015 2015 2015 2015 (in thousands except share and per share amounts) Revenue $ 36,309 $ 6,002 $ 5,736 $ 18,180 $ 66,227 Income (Loss) from operations $ 20,090 $ (8,335 ) $ (10,388 ) $ 1,193 $ 2,560 Net income (loss) attributable to common stockholders $ 19,697 $ (8,177 ) $ (10,167 ) $ 1,218 $ 2,571 Income (loss) per share attributable to common stockholders- basic $ 1.38 $ (0.53 ) $ (0.65 ) $ 0.08 $ 0.17 Income (loss) per share attributable to common stockholders- diluted $ 1.31 $ (0.53 ) $ (0.65 ) $ 0.07 $ 0.16

Organization and Business Act37

Organization and Business Activities (Details)	Nov. 16, 2016USD ($)shares	Nov. 02, 2016	Aug. 03, 2016USD ($)	Aug. 02, 2016	Mar. 29, 2016	Mar. 28, 2016	Jan. 12, 2016USD ($)	Jan. 11, 2016	Nov. 04, 2015USD ($)person	Oct. 13, 2015USD ($)	Mar. 20, 2015USD ($)$ / sharesshares	Feb. 13, 2015USD ($)	Mar. 18, 2014shares	Feb. 18, 2014$ / sharesshares	Oct. 02, 2012shares	Mar. 28, 2012	Dec. 31, 2016USD ($)productshares	Nov. 30, 2016USD ($)	Jan. 31, 2016USD ($)	Dec. 31, 2015USD ($)shares	Mar. 18, 2014USD ($)shares	Feb. 28, 2014USD ($)shares	Dec. 31, 2016productshares	Dec. 31, 2016USD ($)productshares	Sep. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)productshares	Dec. 31, 2015USD ($)shares	Sep. 30, 2014USD ($)shares	Aug. 09, 2016USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of products being sold | product																	5						5	5						5
Aggregate net proceeds received from IPO																					$ 46,069,000							$ 0		$ 0	$ 0	$ 46,069,000
Proceeds from exercise of preferred stock warrants																					$ 21,000	$ 21,000						0		$ 0	$ 0	21,000
Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants (in shares) | shares																					1,788	1,788
Common stock, shares authorized (in shares) | shares																	50,000,000			50,000,000			50,000,000	50,000,000						50,000,000	50,000,000
Preferred stock, shares authorized (in shares) | shares																	1,500,000			1,500,000			1,500,000	1,500,000						1,500,000	1,500,000
Payment for business acquisition																												0		$ 4,850,000	$ 0	0
Proceeds from sale of diclofenac-misoprostol																												0		$ 1,750,000	0	0
Royalty revenue term																10 years
Stock repurchase program, authorized amount																																	$ 75,000,000
Shares of common stock repurchased (in shares) | shares																								276,244						566,838
Value of common stock repurchased																								$ 19,000,000						$ 37,003,000
Other revenue																												$ 0		49,796,000	$ 45,000,000	$ 3,765,000
IPO
Subsidiary, Sale of Stock [Line Items]
Reverse stock split in connection with IPO														0.1560
Common stock, shares authorized (in shares) | shares														50,000,000
Preferred stock, shares authorized (in shares) | shares														1,500,000
Follow-on Offering
Subsidiary, Sale of Stock [Line Items]
Other offering expenses payable											$ 54,331,000
Common stock
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock, (in shares) | shares															1,395,226
Common stock | IPO
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs (in shares) | shares														3,350,000
IPO share price (usd per share) | $ / shares														$ 15
Common stock | Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs (in shares) | shares													100,000
Common stock | Follow-on Offering
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs (in shares) | shares											1,388,517
IPO share price (usd per share) | $ / shares											$ 42
Underwritten public offering (in shares) | shares											1,518,317
Issuance of common stock, additional period underwriters may purchase											30 days
Issuance of common stock, number of shares underwriters may purchase during additional period (in shares) | shares											198,041
Issuance of common stock, portion from company in SPO (in shares) | shares											129,800
Preferred stock | IPO
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock, (in shares) | shares														7,487,928
Warrants | IPO
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock, (in shares) | shares														32,286
Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Upfront cash (payment) proceeds for license agreement												$ 30,000,000							$ 30,000,000	$ 15,000,000
Licensing agreement, milestone proceeds																		$ 40,000,000	15,000,000
Maximum additional milestone payments																														$ 25,000,000
Royalty payments if product is approved, percentage of net sales												20.00%						25.00%
Other revenue																											$ 30,000,000
Licensing agreement, proceeds from unique billing code																	$ 40,000,000	$ 40,000,000						$ 40,000,000
Minimum | Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Royalty payments if product is approved, percentage of net sales		20.00%										20.00%					20.00%
Maximum | Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Royalty payments if product is approved, percentage of net sales																	25.00%	25.00%					25.00%
Affiliated Entity | Spectrum | Spectrum Agreement
Subsidiary, Sale of Stock [Line Items]
Percentage of time allocation									80.00%
Number of employees, Corporate Accounting Sales Team | person									32
Base fee									$ 12,800,000
Related party, service period, extension option									6 months
Entity number of employees | person									50
Affiliated Entity | Albany Molecular Research, Inc. | Jointly Develop and Manufacture Drug Products
Subsidiary, Sale of Stock [Line Items]
Related party, cost sharing, percentage								37.50%
Albany Molecular Research, Inc. | Affiliated Entity | Jointly Develop and Manufacture Drug Products
Subsidiary, Sale of Stock [Line Items]
Related party, cost sharing, percentage								62.50%
Bendeka
Subsidiary, Sale of Stock [Line Items]
Exclusive rights, term						7 years
Bendeka | Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Other revenue																									$ 1,750,000
Proceeds receivable upon each regulatory approval																									750,000				$ 750,000
Proceeds receivable upon regulatory approvals, maximum																									$ 2,250,000				$ 2,250,000
Ryanodex
Subsidiary, Sale of Stock [Line Items]
Royalty payments if product is approved, percentage of net sales			3.00%	15.00%
Intellectual Property
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of diclofenac-misoprostol																										$ 1,750,000
Royalty revenue, percentage of gross profits					25.00%																								25.00%
Royalty revenue term					5 years																								5 years
Ryanodex intangible | Ryanodex
Subsidiary, Sale of Stock [Line Items]
Proceeds from agreement to reduce royalty revenue percentage			$ 15,000,000
Non-Alcohol Docetaxel Injection | Docetaxel product rights
Subsidiary, Sale of Stock [Line Items]
Payment for business acquisition							$ 4,850,000			$ 250,000									$ 4,850,000
Eagle Biologics
Subsidiary, Sale of Stock [Line Items]
Payment for business acquisition	$ 27,209,000
Shares issued to acquire business (in shares) | shares	40,200
Business combination, stock consideration transfered, amount	$ 3,046,000
Common stock
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs (in shares) | shares																															1,389,000	3,450,000
Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants (in shares) | shares																																2,000
Common stock | Warrants
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock, (in shares) | shares																																32,000
Royalties on Gross Profits | Non-Alcohol Docetaxel Injection | Docetaxel product rights
Subsidiary, Sale of Stock [Line Items]
Royalties, percentage of gross profits							25.00%												25.00%
Milestone Payments | Eagle Biologics
Subsidiary, Sale of Stock [Line Items]
Contingent consideration liability	48,000,000
Business combination, consideration transfered, including contingent consideration	$ 78,000,000

Transition Period (Details)

Transition Period (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Revenue:
Product sales									$ 1,506	$ 2,224	$ 40,646	$ 12,968	$ 4,626
Royalty revenue									4,094	3,268	99,040	8,259	10,708
Total revenue	$ 81,140	$ 37,833	$ 40,918	$ 29,591	$ 18,180	$ 5,736	$ 6,002	$ 36,309	5,600	5,492	189,482	66,227	19,099
Operating expenses:
Cost of product sales									1,782	2,670
Cost of royalty revenue									2,707	1,954	20,986	7,885	6,672
Research and development									3,986	2,589	30,262	27,855	16,816
Selling, general and administrative									3,690	1,344	52,313	20,165	9,326
Total operating expenses									12,165	8,557	136,131	63,667	37,856
Income (Loss) from operations	$ 28,284	$ 12,308	$ 13,656	$ (897)	$ 1,193	$ (10,388)	$ (8,335)	$ 20,090	(6,565)	(3,065)	53,351	2,560	(18,757)
Interest income									1	1	84	25	31
Interest expense									(1)	0	(8)	(11)	(8)
Change in value of warrant liability									0	(191)	0	0	(573)
Total other income/(expense)									0	(190)	76	14	(515)
Income (Loss) before income tax benefit									(6,565)	(3,255)	53,427	2,574	(19,272)
Benefit from (provision for) income taxes									1,059	0	28,026	(3)	1,295
Net Income (Loss)									(5,506)	(3,255)	81,453	2,571	(17,977)
Less dividends on Series A, B, B-1 and C Convertible Preferred Stock									0	(1,132)	$ 0	$ 0	$ (1,666)
Net income (loss) attributable to common stockholders									$ (5,506)	$ (4,387)
Loss per share attributable to common stockholders Basic and diluted (in dollars per share)									$ (0.39)	$ (1.44)
Weighted average common shares outstanding Basic and diluted (in shares)									14,032,828	3,048,131

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Narrative (Details)	Nov. 02, 2016	Feb. 13, 2015USD ($)	Dec. 31, 2016USD ($)shares	Nov. 30, 2016USD ($)	Jan. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016shares	Dec. 31, 2016USD ($)shares	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2016USD ($)vendorshares	Dec. 31, 2015USD ($)	Sep. 30, 2014USD ($)
Short-term Debt [Line Items]
Warrants outstanding (in shares) | shares			0				0	0				0
Definite-lived intangible asset impairment										$ 0		$ 0	$ 0	$ 0
Goodwill impairment										0		0	0	0
Advertising and marketing costs										1,556,000		14,784,000	4,752,000	2,506,000
Income tax (provision) benefit										1,059,000	$ 0	28,026,000	(3,000)	1,295,000
Other revenue										$ 0		49,796,000	$ 45,000,000	$ 3,765,000
Cephalon, Inc.
Short-term Debt [Line Items]
Upfront cash proceeds for license agreement		$ 30,000,000			$ 30,000,000	$ 15,000,000
Licensing agreement, milestone proceeds				$ 40,000,000	$ 15,000,000
Licensing agreement, proceeds from unique billing code			$ 40,000,000	$ 40,000,000				$ 40,000,000
Royalty payments if product is approved, percentage of net sales		20.00%		25.00%
Maximum additional milestone payments												$ 25,000,000
Other revenue									$ 30,000,000
Argatroban
Short-term Debt [Line Items]
Number of vendors | vendor												1
Minimum | Cephalon, Inc.
Short-term Debt [Line Items]
Royalty payments if product is approved, percentage of net sales	20.00%	20.00%	20.00%
Maximum | Cephalon, Inc.
Short-term Debt [Line Items]
Royalty payments if product is approved, percentage of net sales			25.00%	25.00%			25.00%
Bendeka
Short-term Debt [Line Items]
Reporting term for partners' net product sales, royalty revenue												25 days
Argatroban
Short-term Debt [Line Items]
Reporting term for partners' net product sales, royalty revenue												60 days

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Major Customers as a Percentage (Details) - Customer Concentration Risk	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Net Revenues
Concentration Risk [Line Items]
Percentage of concentration	100.00%	100.00%	100.00%	100.00%
Net Revenues | The Medicines Company/Chiesi USA, Inc.
Concentration Risk [Line Items]
Percentage of concentration	36.00%	4.00%	14.00%	45.00%
Net Revenues | Sandoz, Inc.
Concentration Risk [Line Items]
Percentage of concentration	55.00%	5.00%	5.00%	53.00%
Net Revenues | Cephalon, Inc. (Teva)
Concentration Risk [Line Items]
Percentage of concentration	0.00%	79.00%	68.00%	0.00%
Net Revenues | Other
Concentration Risk [Line Items]
Percentage of concentration	9.00%	12.00%	13.00%	2.00%
Accounts Receivable
Concentration Risk [Line Items]
Percentage of concentration		100.00%	100.00%
Accounts Receivable | The Medicines Company/Chiesi USA, Inc.
Concentration Risk [Line Items]
Percentage of concentration		3.00%	35.00%
Accounts Receivable | Sandoz, Inc.
Concentration Risk [Line Items]
Percentage of concentration		8.00%	0.00%
Accounts Receivable | Cephalon, Inc. (Teva)
Concentration Risk [Line Items]
Percentage of concentration		74.00%	57.00%
Accounts Receivable | Other
Concentration Risk [Line Items]
Percentage of concentration		15.00%	8.00%

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Common Shares Equivalents Outstanding (Details) - shares	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	1,302,685	869,957	96,610	3,871,141
Series A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	0	0	0	888,099
Series B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	0	0	0	754,191
Series B-1
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	0	0	0	554,382
Series C
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	0	0	0	654,896
Series C warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	0	0	0	56,078
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	1,302,685	869,957	96,610	963,495

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Accounting Policies [Abstract]
Numerator for basic and diluted earnings per share-net income (loss)	$ 57,298	$ 11,952	$ 13,099	$ (896)	$ 1,218	$ (10,167)	$ (8,177)	$ 19,697	$ (5,506)	$ 81,453	$ 2,571	$ (19,643)
Basic weighted average common shares outstanding (in shares)									14,032,828	15,533,681	15,250,154	9,955,937
Dilutive effect of stock options (in shares)									0	900,423	1,003,627	0
Diluted weighted average common shares outstanding (in shares)									14,032,828	16,434,104	16,253,781	9,955,937
Basic (in dollars per share)	$ 3.75	$ 0.77	$ 0.84	$ (0.06)	$ 0.08	$ (0.65)	$ (0.53)	$ 1.38	$ (0.39)	$ 5.24	$ 0.17	$ (1.97)
Diluted (in dollars per share)	$ 3.52	$ 0.73	$ 0.80	$ (0.06)	$ 0.07	$ (0.65)	$ (0.53)	$ 1.31	$ (0.39)	$ 4.96	$ 0.16	$ (1.97)

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw material	$ 1,131	$ 8,687
Work in process	900	6,044
Finished products	708	311
Inventories	$ 2,739	$ 15,042

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Property, Plant and Equipment [Line Items]
Property and equipment		$ 4,822	$ 3,070
Less accumulated depreciation		(1,506)	(865)
Property and equipment, net		3,316	2,205
Depreciation expense	$ 13	641	112	$ 104
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property and equipment		$ 1,121	582
Estimated Useful Life (years)		7 years
Office equipment
Property, Plant and Equipment [Line Items]
Property and equipment		$ 513	328
Estimated Useful Life (years)		3 years
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment		$ 2,059	1,182
Estimated Useful Life (years)		7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment		$ 1,129	$ 978
Estimated Useful Life (years)		2 years

Balance Sheet Accounts - Prepai

Balance Sheet Accounts - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Advances to commercial manufacturers	$ 7,600	$ 85
Prepaid FDA user fee	1,592	551
Prepaid insurance	135	218
Prepaid research and development	21	283
Prepaid income taxes	1,654	508
All other	355	220
Total Prepaid expenses and other current assets	$ 11,357	$ 1,865

Balance Sheet Accounts - Accrue

Balance Sheet Accounts - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Components of Accrued Expenses [Line Items]
Accrued research & development	$ 3,528	$ 1,784
Accrued professional fees	2,094	792
Accrued salary and other compensation	6,003	2,242
Accrued product costs	2,856	9,232
All other	1,688	521
Total Accrued expenses	25,237	24,405
Chiesi USA Inc./The Medicines Company
Components of Accrued Expenses [Line Items]
Royalties due	1,030	6,948
SciDose
Components of Accrued Expenses [Line Items]
Royalties due	8,038	1,637
Sandoz, Inc.
Components of Accrued Expenses [Line Items]
Royalties due	$ 0	$ 1,249

Balance Sheet Accounts - Deferr

Balance Sheet Accounts - Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 0	$ 6,000
Asset sales
Deferred Revenue Arrangement [Line Items]
Deferred revenue	0	6,000
Par Pharmaceutical, Inc. | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	0	5,500
Par Pharmaceuticals Companies, Inc./Tech Transfer | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 0	$ 500

Notes Payable (Details)

Notes Payable (Details)

Feb. 18, 2014USD ($)shares

Oct. 02, 2012shares

Mar. 18, 2014USD ($)shares

Feb. 28, 2014USD ($)shares

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2016USD ($)$ / sharesshares

Dec. 31, 2015USD ($)shares

Sep. 30, 2014USD ($)

Dec. 31, 2012tranche

Sep. 26, 2012USD ($)shares

Aug. 02, 2012$ / shares

Short-term Debt [Line Items]

Warrants outstanding (in shares) | shares

0

Expected term of warrants

6 years

Warrant, term commencement option, period after closing date

1 year

Proceeds from exercise of preferred stock warrants | $

$ 21,000

$ 21,000

$ 0

$ 0

$ 0

$ 21,000

Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants (in shares) | shares

1,788

1,788

Change in fair value of warrant liability | $

0

$ 191,000

$ 0

$ 0

573,000

Redeemable Convertible Preferred Stock

Short-term Debt [Line Items]

Conversion of stock, shares converted (in shares) | shares

8,943,447

Common stock

Short-term Debt [Line Items]

Conversion of preferred shares to common stock | shares

1,395,226

Series C Convertible Preferred Stock

Short-term Debt [Line Items]

Conversion of preferred shares to common stock | shares

1,719,693

Convertible Note and Warrant Purchase Agreement

Short-term Debt [Line Items]

Warrants monthly accrual rate

2.00%

Warrants outstanding (in shares) | shares

0

0

944,210

Warrants liability | $

$ 2,280,000

Warrants exercise price (in usd per share) | $ / shares

$ 1.82

Change in fair value of warrant liability | $

$ 0

$ 0

$ 573,000

Convertible Note and Warrant Purchase Agreement | Other income and expense

Short-term Debt [Line Items]

Change in fair value of warrant liability | $

$ 383,000

Convertible Note and Warrant Purchase Agreement | Warrants

Short-term Debt [Line Items]

Fair value assumptions, exercise price (in usd per share) | $ / shares

$ 1.82

Fair value assumptions, implied stock price (in usd per share) | $ / shares

$ 1.82

Fair value assumptions, expected volatility

64.00%

Fair value assumptions, expected dividend rate

6.00%

Fair value assumptions, risk free interest rate

0.83%

Fair value assumptions, expiration term

6 years

Convertible Note and Warrant Purchase Agreement | Series C Convertible Preferred Stock | Warrants

Short-term Debt [Line Items]

Convertible preferred stock, liquidation preference multiple

2

Convertible Note and Warrant Purchase Agreement | Convertible notes payable

Short-term Debt [Line Items]

Convertible Notes issued | $

$ 9,662,755

Number of tranches | tranche

2

Annual interest rate

6.00%

Conversion price pursuant to conversion terms at maturity date (in usd per share) | $ / shares

$ 1.82

IPO | Warrants

Short-term Debt [Line Items]

Conversion of preferred shares to common stock | shares

32,286

Probability-Weighted Expected Returns Valuation Model | Convertible Note and Warrant Purchase Agreement

Short-term Debt [Line Items]

Warrants liability | $

$ 655,000

Shares Subject to Redemption 49

Shares Subject to Redemption — Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 18, 2014	Feb. 18, 2014	Apr. 11, 2013	Aug. 11, 2008	Mar. 08, 2007	Dec. 31, 2014	Jul. 31, 2011	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014	Sep. 30, 2013	Aug. 02, 2012
Temporary Equity [Line Items]
Offering cost						$ 0		$ 0	$ 0	$ 1
Series A Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued (in shares)					20,237,911
Par value per share of Convertible Preferred Stock (in usd per share)					$ 0.001
Convertible Preferred Stock original issue price per share					$ 0.971
Conversion of preferred shares to common stock, (in shares)	2,332,051
Estimated fair value of convertible preferred stock					$ 19,651
Offering cost					$ 180
Accumulated dividends on the Preferred Stock	$ 97	$ 97
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued (in shares)				16,052,343
Par value per share of Convertible Preferred Stock (in usd per share)				$ 0.001
Convertible Preferred Stock original issue price per share				$ 1.82
Conversion of preferred shares to common stock, (in shares)	1,980,431
Estimated fair value of convertible preferred stock				$ 29,215
Offering cost				$ 126
Accumulated dividends on the Preferred Stock	$ 173	$ 173
Series B-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued (in shares)							10,177,085
Par value per share of Convertible Preferred Stock (in usd per share)							$ 0.001
Convertible Preferred Stock original issue price per share							$ 1.82
Conversion of preferred shares to common stock, (in shares)		1,455,753
Estimated fair value of convertible preferred stock							$ 17,522
Offering cost							$ 144
Accumulated dividends on the Preferred Stock	$ 125	$ 125
Shares of Series B-1 Preferred Stock in exchange for satisfaction of the principal amount of debt												549,451
Convertible preferred stock, shares outstanding (in shares)											9,331,374
Series C Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued (in shares)			11,023,232
Par value per share of Convertible Preferred Stock (in usd per share)			$ 0.001
Convertible Preferred Stock original issue price per share			$ 1.82
Conversion of preferred shares to common stock, (in shares)	1,719,693
Estimated fair value of convertible preferred stock			$ 20,062
Offering cost			$ 167
Accumulated dividends on the Preferred Stock	$ 139	$ 139

Common Stock and Stock-Based 50

Common Stock and Stock-Based Compensation - Narrative (Details) - USD ($)	Aug. 04, 2015	Jun. 30, 2016	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Aug. 09, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount								$ 75,000,000
Share-based payment award, award vesting period				4 years
Number of shares available for grant (in shares)				2,106,545
Weighted-average grant-date fair value of options granted (in usd per share)			$ 6.73	$ 27.79	$ 15.92		$ 4.61
Unrecognized compensation cost				$ 15,476,000
Total intrinsic value of options exercised				$ 11,521,000
Number of stock options exercised (in shares)			4,513	214,194	211,190
Weighted average contractual terms of options outstanding				7 years	7 years 6 months	7 years 6 months	7 years 6 months
Aggregate pre-tax intrinsic value of options outstanding			$ 9,600,000	$ 59,200,000	$ 54,700,000	$ 9,600,000	$ 5,900,000
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, number of additional shares authorized (in shares)	500,000
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Plan modification, reversal of previously recognized expense for unvested options		$ 0
Plan modification, expense related to acceleration of unvested options		$ 0
Unrecognized compensation cost expense term				4 years

Common Stock and Stock-Based 51

Common Stock and Stock-Based Compensation - Schedule of Common Stock Repurchase (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares of common stock repurchased (in shares)	276,244	566,838
Value of common stock repurchased	$ 19,000	$ 37,003

Common Stock and Stock-Based 52

Common Stock and Stock-Based Compensation - Fair Value of Share Options Granted (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest minimum rate	2.11%	0.94%	1.42%	1.77%
Risk-free interest maximum rate	2.16%	2.34%	2.09%	2.16%
Volatility maximum rate	39.45%	30.95%	28.40%	33.64%
Volatility minimum rate		32.36%	32.90%	64.00%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 7 months 2 days	5 years 15 days	5 years 6 months	6 years 26 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years	7 years	7 years	9 years 4 months 21 days

Common Stock and Stock-Based 53

Common Stock and Stock-Based Compensation - Recognized Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 284	$ 9,768	$ 4,051	$ 606
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	144	7,073	2,780	303
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 140	$ 2,695	$ 1,271	$ 303

Common Stock and Stock-Based 54

Common Stock and Stock-Based Compensation - Share-based Compensation, Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Stock Option Shares Outstanding, Beginning Balance (in shares)	1,308,993	1,844,842	1,322,170
Number of Stock Option Shares, Granted (in shares)	29,000	792,500	773,458
Number of Stock Option Shares, Exercised (in shares)	(4,513)	(214,194)	(211,190)
Number of Stock Option Shares, Forfeited or expired (in shares)	(11,310)	(98,230)	(39,596)
Number of Stock Option Shares Outstanding, Ending Balance (in shares)	1,322,170	2,324,918	1,844,842	1,308,993
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price of Options Outstanding, Beginning Balance (in usd per share)	$ 8.16	$ 25.16	$ 8.29
Weighted Average Exercise Price of Stock Options Granted (in usd per share)	12.61	81.61	48.65
Weighted Average Exercise Price of Stock Options Exercised (in usd per share)	7.62	16.94	7.06
Weighted Average Exercise Price of Options Outstanding, Ending Balance (in usd per share)	$ 8.29	$ 44.53	$ 25.16	$ 8.16
Non- Exercisable options outstanding (in shares)	710,486	1,281,208	1,176,140	712,901
Exercisable options outstanding (in shares)	611,684	1,043,710	668,702	596,092

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax (Benefit) Expense (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Current:
Federal	$ 0		$ (1,175)	$ 0	$ 0
State	1,059		(919)	(3)	1,295
Total	1,059		(2,094)	(3)	1,295
Deferred:
Federal	0		29,553	0	0
State	0		567	0	0
Total	0		30,120	0	0
Benefit from (provision for) income taxes	$ 1,059	$ 0	$ 28,026	$ (3)	$ 1,295

Income Taxes - Reconciliation (

Income Taxes - Reconciliation (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Federal statutory tax rate	34.00%	35.00%	34.00%	34.00%
State income taxes, net of federal benefit	16.00%	3.00%	0.00%	7.00%
Tax benefit on stock option exercises	(0.00%)	(7.00%)	(0.00%)	(0.00%)
Tax credits	(3.00%)	(3.00%)	(10.00%)	(1.00%)
Other	0.00%	(1.00%)	1.00%	(1.00%)
Change in valuation allowance	(31.00%)	(79.00%)	(25.00%)	(32.00%)
Effective tax rate	16.00%	(52.00%)	0.00%	7.00%

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 17,700	$ 30,837
Stock based compensation	5,185	2,100
Research and development tax credit carryforwards	4,993	2,790
Accrued bonus and other employee related expenses	1,946	741
Prepaid R&D expenses	1,643	1,884
Other	285	254
Total deferred tax assets	31,752	38,606
Intangible assets	2,944	0
Prepaid expenses	80	81
Fixed assets	78	0
Other	7	7
Total deferred tax liabilities	3,109	88
Valuation allowance	0	(38,518)
Net deferred tax assets	$ 28,643	$ 0

Income Taxes - Narrative (Deta

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Operating Loss Carryforwards [Line Items]
State	$ (1,059)		$ 919	$ 3	$ (1,295)
Sale of NOL	12,588				25,389
Sale of tax credit carryforward	15				177
Benefit from (provision for) income taxes	$ 1,059	$ 0	28,026	$ (3)	$ 1,295
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			50,060
State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			3,435
Research and Development Tax Credit Carryforward | Federal
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, research and development			6,550
Research and Development Tax Credit Carryforward | State
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, research and development			$ 4

License Agreements of Develop59

License Agreements of Development and Commercialization Rights (Details)	Feb. 13, 2015USD ($)	Nov. 30, 2016USD ($)	Jan. 31, 2016USD ($)	Dec. 31, 2015USD ($)	May 31, 2008USD ($)	Apr. 30, 2008USD ($)	Dec. 31, 2016USD ($)product	Jul. 31, 2013USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of products with exclusivity rights | product							33
Marketing rights, term							10 years
Collaborative product development agreement, non-refundable revenue for signing					$ 750,000
Cumulative milestones upon achievement of goals					13,000,000
Collaborative product development agreement, payment for product development					$ 2,000,000
Collaborative product development agreement monthly revenue						$ 200,000
Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative product development agreement, term of exclusive marketing rights for partner					10 years
Contract Termination
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative product development agreement, expected future receivables								$ 0
Cephalon, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront cash (payment) proceeds for license agreement	$ 30,000,000		$ 30,000,000	$ 15,000,000
Licensing agreement, milestone proceeds		$ 40,000,000	15,000,000
Maximum additional milestone payments							$ 25,000,000
Royalty payments if product is approved, percentage of net sales	20.00%	25.00%
Teikoku
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Licensing agreement, milestone proceeds			$ 4,850,000

Asset Sales (Details)

Asset Sales (Details) - USD ($)

Mar. 29, 2016

Jun. 30, 2014

Mar. 14, 2014

Jun. 24, 2013

Mar. 28, 2012

Mar. 31, 2016

Dec. 31, 2014

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Sep. 30, 2014

Sep. 30, 2011

Deferred Revenue Arrangement [Line Items]

Expected cash proceeds upon regulatory approval milestone

$ 1,000,000

Milestone reduction

$ 500,000

Royalty revenue term

10 years

Divestiture of businesses proceeds

$ 6,500,000

Proceeds from sale of diclofenac-misoprostol

$ 0

$ 1,750,000

$ 0

$ 0

Asset sales

Deferred Revenue Arrangement [Line Items]

Deferred revenue, noncurrent

$ 6,000

6,000

Asset sales | Hikma Pharmaceuticals, Co. Ltd.

Deferred Revenue Arrangement [Line Items]

Milestone method, revenue recognized

$ 3,500,000

$ 3,500,000

$ 3,500,000

$ 3,500,000

Par Pharmaceutical, Inc. | Par Pharmaceuticals Companies, Inc.

Deferred Revenue Arrangement [Line Items]

Deferred revenue, noncurrent

5,500,000

Initiation of Tech Transfer | Par Pharmaceuticals Companies, Inc.

Deferred Revenue Arrangement [Line Items]

Divestiture of businesses proceeds

500,000

Deferred revenue, noncurrent

250,000

Completion of Tech Transfer | Par Pharmaceuticals Companies, Inc.

Deferred Revenue Arrangement [Line Items]

Divestiture of businesses proceeds

500,000

Deferred revenue, noncurrent

$ 250,000

Intellectual Property

Deferred Revenue Arrangement [Line Items]

Royalty revenue term

5 years

5 years

Proceeds from sale of diclofenac-misoprostol

$ 1,750,000

Royalty revenue, percentage of gross profits

25.00%

25.00%

Commitments (Details)

Commitments (Details) - USD ($) $ in Thousands	Nov. 04, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Long-term Purchase Commitment [Line Items]
Purchase obligation			$ 16,512
Operating leases rent expense		$ 68	634	$ 514	$ 277
Future minimum lease payments			1,973
Base fee payable			4,530
Spectrum Agreement | Spectrum | Affiliated Entity
Long-term Purchase Commitment [Line Items]
Base fee payable			$ 4,530
Service period	18 months

Commitments - Future Minimum Le

Commitments - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2016USD ($)
Operating lease obligations
Operating lease obligation, Total	$ 1,973
Operating lease obligation, 2017	564
Operating lease obligation, 2018	564
Operating lease obligation, 2019	564
Operating lease obligation, 2020	281
Operating lease obligation, 2021	0
Operating lease obligation, beyond	0
Purchase obligations
Purchase Obligation, Total	16,512
Purchase obligation, 2017	16,512
Purchase obligation, 2018	0
Purchase obligation, 2019	0
Purchase obligation, 2020	0
Purchase obligation, 2021	0
Purchase obligation, beyond	0
Due to Related Parties, Noncurrent [Abstract]
Base fee payable, total	4,530
Base fee payable, 2017	4,530
Base fee payable, 2018	0
Base fee payable, 2019	0
Base fee payable, 2020	0
Base fee payable, 2021	0
Base fee payable, beyond	$ 0

Acquistions - Narrative, Docet

Acquistions - Narrative, Docetaxel (Details) - USD ($) $ in Thousands	Jan. 12, 2016	Oct. 13, 2015	Jan. 31, 2016	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Payment for business acquisition				$ 0		$ 4,850	$ 0	$ 0
Product sales				1,506	$ 2,224	40,646	12,968	4,626
Net income (loss)				$ (5,506)	$ (3,255)	81,453	$ 2,571	$ (17,977)
Docetaxel product rights | Non-Alcohol Docetaxel Injection
Business Acquisition [Line Items]
Payment for business acquisition	$ 4,850	$ 250	$ 4,850
Business combination, consideration transferred	$ 11,220
Royalties on Gross Profits | Docetaxel product rights | Non-Alcohol Docetaxel Injection
Business Acquisition [Line Items]
Royalties, percentage of gross profits	25.00%		25.00%
Non-Alcohol Docetaxel Injection
Business Acquisition [Line Items]
Product sales						3,912
Net income (loss)						$ (9,422)

Acquistions - Schedule of Conti

Acquistions - Schedule of Contingent Consideration Fair Value, Docetaxel (Details) - Docetaxel product rights - Contingent Consideration Liability - Non-Alcohol Docetaxel Injection $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Contingent Consideration Liability, Fair Value Rollfoward
Contingent consideration liability, fair value, beginning balance	$ 6,370
Changes in fair value	856
Payment of contingent consideration	(286)
Contingent consideration liability, fair value, ending balance	$ 6,940

Acquistions - Narrative, Biolog

Acquistions - Narrative, Biologics (Details) - USD ($)	Nov. 16, 2016	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Payment for business acquisition			$ 0	$ 4,850,000	$ 0	$ 0
Eagle Biologics
Business Acquisition [Line Items]
Payment for business acquisition	$ 27,209,000
Shares issued to acquire business (in shares)	40,200
Business combination, stock consideration transfered, amount	$ 3,046,000
Opening Balance November 16, 2016	16,100,000	$ 16,201,000		$ 16,201,000
Pro forma revenue of acquiree since acquisition date		40,000
Pro forma loss of acquiree since acquisition date		$ 80,000
Milestone Payments | Eagle Biologics
Business Acquisition [Line Items]
Business combination, consideration transfered, including contingent consideration	78,000,000
Contingent consideration liability	48,000,000
Opening Balance November 16, 2016	$ 16,100,000

Acquistions - Schedule of Consi

Acquistions - Schedule of Consideration Transfered, Biologics (Details) - USD ($) $ in Thousands	Nov. 16, 2016	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Cash consideration paid		$ 0	$ 4,850	$ 0	$ 0
Eagle Biologics
Business Acquisition [Line Items]
Cash consideration paid	$ 27,209
Common stock issued	3,046
Fair value of contingent consideration payable to seller (long term)	16,100
Total consideration	$ 46,355

Acquistions - Schedule of Asset

Acquistions - Schedule of Assets Acquired and Liabilities Assumed, Biologics (Details)	Nov. 16, 2016USD ($)milestone_payment$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Goodwill		$ 39,743,000	$ 0
Eagle Biologics
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and cash equivalents	$ 349,000
Accounts receivable	8,000
Prepaid expenses and other current assets	55,000
Property and equipment	162,000
Developed technology	8,100,000
Total identifiable assets	8,674,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Accounts payable	191,000
Deferred income tax liability, net	1,473,000
Accrued expenses	398,000
Total liabilities assumed	2,062,000
Net assets acquired	6,612,000
Goodwill	39,743,000
Total purchase price	46,355,000
Common shares to be issued value	$ 2,700,000
Average share price, trading days	30 days
Business acquisition, share price (in dollars per share) | $ / shares	$ 68.18
Shares issued to acquire business (in shares) | shares	40,200
Number of milestone payments | milestone_payment	4
Opening Balance November 16, 2016	$ 16,100,000	$ 16,201,000
Expected goodwill tax deduction	$ 0
Developed technology | Eagle Biologics
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Acquired intangible assets, useful life	5 years
Deferred income tax liability	$ 1,500,000
Milestone Payments | Eagle Biologics
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Contingent consideration liability	48,000,000
Opening Balance November 16, 2016	$ 16,100,000

Acquistions - Schedule of Con68

Acquistions - Schedule of Contingent Consideration, Biologic (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Contingent Consideration Liability [Roll Forward]
Change in fair value of contingent consideration		$ 0	$ 957	$ 0	$ 0
Payment of contingent consideration		$ 0	(286)	$ 0	$ 0
Eagle Biologics
Contingent Consideration Liability [Roll Forward]
Change in fair value of contingent consideration	$ 101
Payment of contingent consideration	0
Closing Balance December 31, 2016	$ 16,201		$ 16,201

Acquistions - Schedule of Pro F

Acquistions - Schedule of Pro Forma Information, Biologic (Details) - USD ($) $ / shares in Units, $ in Thousands	Nov. 16, 2016	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Selling, general and administrative		$ 3,690	$ 1,344	$ 52,313	$ 20,165	$ 9,326
Eagle Biologics
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Total revenue				193,050	67,117
Net income				$ 75,410	$ 608
Basic (in dollars per share)				$ 4.85	$ 0.04
Diluted (in dollars per share)				$ 4.59	$ 0.04
Pro forma marginal tax rate, percent	36.00%
Acquisition-related Costs | Eagle Biologics
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Selling, general and administrative				$ 700

Intangible Assets, Net - Sched

Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 34,320	$ 0
Accumulated Amortization		(948)	0
Net Book Value		33,372	0
Amortization expense	$ 0	$ 948	0	$ 0
Docetaxel product rights
Finite-Lived Intangible Assets [Line Items]
Useful Life (In Years)		18 years
Gross Carrying Amount		$ 11,220	0
Accumulated Amortization		(571)	0
Net Book Value		$ 10,649	$ 0
Ryanodex intangible
Finite-Lived Intangible Assets [Line Items]
Useful Life (In Years)		20 years
Gross Carrying Amount		$ 15,000
Accumulated Amortization		(174)
Net Book Value		$ 14,826
Developed technology
Finite-Lived Intangible Assets [Line Items]
Useful Life (In Years)		5 years
Gross Carrying Amount		$ 8,100
Accumulated Amortization		(203)
Net Book Value		$ 7,897

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 2,846
2,018	3,021
2,019	3,143
2,020	3,289
2,021	3,246
All other	17,827
Net Book Value	$ 33,372	$ 0

Selected Quarterly Financial 72

Selected Quarterly Financial Data - Unaudited (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2014
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 81,140	$ 37,833	$ 40,918	$ 29,591	$ 18,180	$ 5,736	$ 6,002	$ 36,309	$ 5,600	$ 5,492	$ 189,482	$ 66,227	$ 19,099
Income (Loss) from operations	28,284	12,308	13,656	(897)	1,193	(10,388)	(8,335)	20,090	(6,565)	$ (3,065)	53,351	2,560	(18,757)
Net income (loss) attributable to common stockholders	$ 57,298	$ 11,952	$ 13,099	$ (896)	$ 1,218	$ (10,167)	$ (8,177)	$ 19,697	$ (5,506)		$ 81,453	$ 2,571	$ (19,643)
Income (loss) per share attributable to common stockholders- basic (in dollars per share)	$ 3.75	$ 0.77	$ 0.84	$ (0.06)	$ 0.08	$ (0.65)	$ (0.53)	$ 1.38	$ (0.39)		$ 5.24	$ 0.17	$ (1.97)
Income (loss) per share attributable to common stockholders- diluted (in dollars per share)	$ 3.52	$ 0.73	$ 0.80	$ (0.06)	$ 0.07	$ (0.65)	$ (0.53)	$ 1.31	$ (0.39)		$ 4.96	$ 0.16	$ (1.97)

Subsequent Events - Narrative (

Subsequent Events - Narrative (Details) - USD ($)	Jan. 26, 2017	Dec. 31, 2016
Line of Credit | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Credit agreement, term	3 years
Line of credit facility, maximum borrowing capacity	$ 50,000,000
Line of Credit | Letter of Credit | Subsequent Event
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of Credit | Minimum | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Commitment fee percentage	0.35%
Line of Credit | Maximum | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Commitment fee percentage	0.40%
Line of Credit | London Interbank Offered Rate (LIBOR) | Minimum | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Interest rate margin	2.50%
Line of Credit | London Interbank Offered Rate (LIBOR) | Maximum | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Interest rate margin	3.00%
Line of Credit | Prime Rate | Minimum | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Interest rate margin	1.50%
Line of Credit | Prime Rate | Maximum | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Interest rate margin	2.00%
Cephalon, Inc.
Subsequent Event [Line Items]
Maximum additional milestone payments		$ 25,000,000
Teva Pharmaceuticals | Cephalon, Inc.
Subsequent Event [Line Items]
Milestone payment benchmark, net sales		$ 500,000,000